

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptasxm1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* \* \* \* \* Welcome to STN International \* \* \* \* \* \* \* \* \*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 JAN 02 STN pricing information for 2008 now available  
NEWS 3 JAN 16 CAS patent coverage enhanced to include exemplified prophetic substances  
NEWS 4 JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats  
NEWS 5 JAN 28 MARPAT searching enhanced  
NEWS 6 JAN 28 USGENE now provides USPTO sequence data within 3 days of publication  
NEWS 7 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment  
NEWS 8 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements  
NEWS 9 FEB 08 STN Express, Version 8.3, now available  
NEWS 10 FEB 20 PCI now available as a replacement to DPCI  
NEWS 11 FEB 25 IFIREF reloaded with enhancements  
NEWS 12 FEB 25 IMSPRODUCT reloaded with enhancements  
NEWS 13 FEB 29 WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification  
NEWS 14 MAR 31 IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats  
NEWS 15 MAR 31 CAS REGISTRY enhanced with additional experimental spectra  
NEWS 16 MAR 31 CA/CAplus and CASREACT patent number format for U.S. applications updated  
NEWS 17 MAR 31 LPCI now available as a replacement to LDPCI  
NEWS 18 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements  
NEWS 19 APR 04 STN AnaVist, Version 1, to be discontinued

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 19:53:10 ON 09 APR 2008

FILE 'REGISTRY' ENTERED AT 19:53:27 ON 09 APR 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 8 APR 2008 HIGHEST RN 1012980-81-2  
DICTIONARY FILE UPDATES: 8 APR 2008 HIGHEST RN 1012980-81-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.



TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stn/gen/stndoc/properties.html>

=>  
Uploading C:\Program Files\Stnexp\Queries\10539936.str



chain nodes :  
10 11 12 14 16 19

```

ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
1-19 2-14 4-12 7-16 8-10 10-11
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
1-2 1-6 1-19 2-3 2-14 3-4 4-5 4-12 5-6 6-9 7-8 7-16 8-9 8-10 10-11
exact bonds :
5-7
isolated ring systems :
containing 1 :

```

G1:H,O,S,N

G2:O,S,N

G3:H,Cy,Ak,O,N

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:Atom 12:CLASS 14:CLASS 16:Atom 19:CLASS


```

L1 STRUCTURE UPLOADED

```

=> d 11
L1 HAS NO ANSWERS
L1 STR

```



G1 H,O,S,N

G2 O,S,N

G3 H,Cy,Ak,O,N

Structure attributes must be viewed using STN Express query preparation.

```

=> s 11 sam
SAMPLE SEARCH INITIATED 19:54:11 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1051 TO ITERATE

```

100.0% PROCESSED 1051 ITERATIONS  
SEARCH TIME: 00.00.01

13 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 19076 TO 22964  
PROJECTED ANSWERS: 44 TO 476

L2 13 SEA SSS SAM L1

=> s l1 ful  
FULL SEARCH INITIATED 19:54:18 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 21423 TO ITERATE

100.0% PROCESSED 21423 ITERATIONS 373 ANSWERS  
SEARCH TIME: 00.00.01

L3 373 SEA SSS FUL L1

=> fil cap1  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
SESSION  
FULL ESTIMATED COST 178.82 179.03

FILE 'CAPLUS' ENTERED AT 19:54:25 ON 09 APR 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Apr 2008 VOL 148 ISS 15  
FILE LAST UPDATED: 8 Apr 2008 (20080408/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>


=> s 13  
L4 10 L3

=> s l4 ibib hitstr abs 1-10  
MISSING OPERATOR L4 IBIB  
The search profile that was entered contains terms or nested terms that are not separated by a logical operator.


=> d l4 ibib hitstr abs 1-10



L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2007:661007 CAPLUS  
 DOCUMENT NUMBER: 147:271414  
 TITLE: Exploitation of structural and regulatory diversity in glutamate racemases  
 AUTHOR(S): Lundqvist, Tomas; Fisher, Stewart L.; Kern, Gunther;  
 Folmer, Rutger H. A.; Xue, Yafeng; Newton, D. Trevor;  
 Keating, Thomas A.; Alm, Richard A.; de Jonge,  
 Boudewijn L. M.  
 CORPORATE SOURCE: AstraZeneca Global Structural Chemistry, AstraZeneca  
 R&D Moelndal, Moelndal, SE-431 83, Swed.  
 SOURCE: Nature (London, United Kingdom) (2007), 447(7146),  
 817-822  
 CODEN: NATUAS; ISSN: 0028-0836  
 PUBLISHER: Nature Publishing Group  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 482584-49-6DP, complexes with glutamate racemase  
 RL: BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (exploitation of structural and regulatory diversity in glutamate racemases)  
 RN 482584-49-6 CAPLUS  
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)- (CA INDEX NAME)



IT 946411-72-9P  
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);  
 BIOL (Biological study); PREP (Preparation)  
 (exploitation of structural and regulatory diversity in glutamate racemases)  
 RN 946411-72-9 CAPLUS  
 CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)



AB    Glutamate racemase is an enzyme essential to the bacterial cell wall biosynthesis pathway, and has therefore been considered as a target for antibacterial drug discovery. We characterized the glutamate racemases of several pathogenic bacteria using structural and biochem. approaches. Here we describe three distinct mechanisms of regulation for the family of glutamate racemases: allosteric activation by metabolic precursors, kinetic regulation through substrate inhibition, and D-glutamate recycling using a D-amino acid transaminase. In a search for selective inhibitors, we identified a series of uncompetitive inhibitors specifically targeting *Helicobacter pylori* glutamate racemase that bind to a cryptic allosteric site, and used these inhibitors to probe the mechanistic and dynamic features of the enzyme. These structural, kinetic and mutational studies provide insight into the physiol. regulation of these essential enzymes and provide a basis for designing narrow-spectrum antimicrobial agents.


REFERENCE COUNT:                    27                    THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2005:1154366 CAPLUS  
 DOCUMENT NUMBER: 143:422361  
 TITLE: Preparation of cyclic compounds as CRF receptor antagonists  
 INVENTOR(S): Gyorkos, Albert Charles; Corrette, Christopher Peter;  
 Cho, Suk Young; Turner, Timothy Mark; Aso, Kazuyoshi;  
 Kori, Masakuni; Gyoten, Michiyo; Condroski, Kevin  
 Ronald; Siedem, Christopher Stephen; Boyd, Steven  
 Armen  
 PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Japan; et al.  
 SOURCE: PCT Int. Appl., 354 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005099688	A2	20051027	WO 2005-US13583	20050406
WO 2005099688	A3	20070531		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AP, EA, EP, OA				
CA 2562244	A1	20051027	CA 2005-2562244	20050406
EP 1732541	A2	20061220	EP 2005-741906	20050406
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
JP 2007532580	T	20071115	JP 2007-507576	20050406
US 20070179165	A1	20070802	US 2007-593891	20070405
PRIORITY APPLN. INFO.:			US 2004-560286P	P 20040407
			WO 2005-US13583	W 20050406

OTHER SOURCE(S): MARPAT 143:422361  
 IT 868374-31-6P, (6Z)-2-Benzyl-6-(cyclopropylimino)-3-mesityl-5-  
 methyl-7-propyl-2,5,6,7-tetrahydro-4H-pyrazolo[3,4-d]pyrimidin-4-one  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (drug candidate; preparation of cyclic compds. as CRF receptor antagonists  
 with therapeutic potential)  
 RN 868374-31-6 CAPLUS  
 CN 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 6-(cyclopropylimino)-2,5,6,7-tetrahydro-  
 5-methyl-2-(phenylmethyl)-7-propyl-3-(2,4,6-trimethylphenyl)-, (6Z)- (CA  
 INDEX NAME)


Double bond geometry as shown.




IT 868371-84-0P, 2-Benzyl-3-(2,4-dimethylphenyl)-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (intermediate; preparation of cyclic compds. as CRF receptor antagonists with therapeutic potential)

RN 868371-84-0 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(2,4-dimethylphenyl)-5-methyl-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



GI




AB There are provided corticotropin-releasing factor (CRF) receptor antagonists of formula (I) and (II) [A, B = each independently 5- or 6-membered ring which may be further substituted; D = 5- or 6-membered ring which may be substituted; R1 = (un)substituted alkyl, substituted amino, hydroxy, etc.; X = CO, O, S, etc.; Y1, Y2, Q = independently (un)substituted C or N; W = a bond, (un)substituted methylene, imino, O, S, etc.; Ar = (un)substituted hetero/aryl; addnl. details are given in the claims; with the exception of certain compds.] or salts thereof or prodrugs thereof. For example, 3-(2,4-dimethylphenyl)-6-dipropylamino-5-


methyl-2,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one was prepared by condensation of 6-hydrazino-3-methylpyrimidine-2,4(1H,3H)-dione (preparation given) with PhCHO, cyclization, chlorination, amination of chloride with di-Pr amine and debenzylation. CRF binding inhibitory rates are tabulated for 7 examples of I. I are useful for treating depression and anxiety (no data).

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2005:158670 CAPLUS  
 DOCUMENT NUMBER: 142:261549  
 TITLE: Preparation of imidazo[1,2-c]pyrazolo[4,3-e]pyrimidine derivatives as glutamate racemase inhibitors  
 INVENTOR(S): Basarab, Gregory S.; Eyermann, Charles J.; Gowravaram, Madhusudhan R.; Green, Oluyinka; Kiely, Andrew; MacPherson, Lawrence J.; Morningstar, Marshall L.; Thanh, Nguyen  
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited  
 SOURCE: PCT Int. Appl., 76 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016929	A1	20050224	WO 2004-GB3464	20040812
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1664052	A1	20060607	EP 2004-743692	20040812
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2007502307	T	20070208	JP 2006-523672	20040812
US 20060252781	A1	20061109	US 2006-567797	20060209
PRIORITY APPLN. INFO.:			US 2003-495615P	P 20030815
			WO 2004-GB3464	W 20040812
OTHER SOURCE(S):	CASREACT 142:261549; MARPAT 142:261549			
IT 719298-19-8P	719298-39-2P	719298-42-7P		
719298-50-7P	719298-78-9P			
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)	(preparation of imidazo[1,2-c]pyrazolo[4,3-e]pyrimidine derivs. as glutamate racemase inhibitors)			
RN 719298-19-8	CAPLUS			
CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-6,7-dihydro-4-[(2-hydroxyethyl)amino]-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-	(CA INDEX NAME)			



RN 719298-39-2 CAPLUS  
 CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-6-oxo-4-thioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-42-7 CAPLUS  
 CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4-hydrazino-6,7-dihydro-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (9CI) (CA INDEX NAME)




RN 719298-50-7 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[4-amino-2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-6,7-dihydro-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-78-9 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)



GI



AB Title compds. represented by the formula I [wherein A = N or (un)substituted C; R = H, halo, (un)substituted alkyl, sulfide, etc.; R<sub>2</sub> = H, (un)substituted (cyclo)alkyl, alkenyl, aryl, etc.; R<sub>3</sub> = (un)substituted hetero(bi)cyclic ring; and pharmaceutically acceptable salts thereof] were prepared as glutamate racemase inhibitors. For example, II was given in a multi-step synthesis starting from the reaction of 6-chlorouracil with cyclopropylmethyl bromide. I showed inhibition of glutamate racemase with IC<sub>50</sub> values of less than 400 uM. Thus, I and their pharmaceutical compns. are useful as glutamate racemase inhibitors for the treatment or prophylaxis of *H. pylori* infection.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2004:589662 CAPLUS  
 DOCUMENT NUMBER: 141:119326  
 TITLE: Crystal structure of bacterial glutamate racemase  
       (MurI) and the design of antibacterial agents  
 INVENTOR(S): Anderson, Marie; Fisher, Stewart Lindsay; Folmer,  
       Rutger Henk Adriaan; Kern, Gunther; Lundqvist, Rolf  
       Tomas; Newton, David Trevor; Xue, Yafeng  
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca Pharmaceuticals LP  
 SOURCE: PCT Int. Appl., 1125 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004061097	A2	20040722	WO 2003-US38977	20031208
WO 2004061097	A3	20040923		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20050037478	A1	20050217	US 2003-729571	20031205
AU 2003302328	A1	20040729	AU 2003-302328	20031208
EP 1573000	A2	20050914	EP 2003-810884	20031208
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:				
		US 2002-435087P	P	20021220
		US 2002-435167P	P	20021220
		US 2002-435272P	P	20021220
		US 2002-435527P	P	20021220
		WO 2003-US38977	W	20031208
IT 482583-54-0D, complexes with glutamate racemase				
482583-72-2D, complexes with glutamate racemase				
482583-80-2D, complexes with glutamate racemase				
482583-92-6D, complexes with glutamate racemase				
482584-43-0D, complexes with glutamate racemase				
482584-49-6D, complexes with glutamate racemase				
482584-60-1D, complexes with glutamate racemase				
482584-67-8D, complexes with glutamate racemase				
482584-95-2D, complexes with glutamate racemase				
482585-01-3D, complexes with glutamate racemase				
482585-68-2D, complexes with glutamate racemase				
482585-73-9D, complexes with glutamate racemase				
482586-39-0D, complexes with glutamate racemase				
482586-96-9D, complexes with glutamate racemase				
482587-04-2D, complexes with glutamate racemase				
482587-09-7D, complexes with glutamate racemase				
482587-14-4D, complexes with glutamate racemase				
719298-33-6D, complexes with glutamate racemase				
719298-34-7D, complexes with glutamate racemase				

719298-35-8D, complexes with glutamate racemase  
 723265-96-1D, complexes with glutamate racemase  
 723265-99-4D, complexes with glutamate racemase  
 723266-01-1D, complexes with glutamate racemase  
 723266-03-3D, complexes with glutamate racemase  
 723266-05-5D, complexes with glutamate racemase  
 723266-08-8D, complexes with glutamate racemase  
 723266-12-4D, complexes with glutamate racemase  
 723266-19-1D, complexes with glutamate racemase  
 723266-22-6D, complexes with glutamate racemase  
 RL: BUU (Biological use, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(crystal structure of bacterial glutamate racemase (MruI) and the design of antibacterial agents)


RN 482583-54-0 CAPLUS

CN Acetamide, N-[4-[4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]- (CA INDEX NAME)



RN 482583-72-2 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-[2-(dimethylamino)ethyl]-1-methyl- (CA INDEX NAME)



RN 482583-80-2 CAPLUS


CN 1H-Pyrrole-3-carboxylic acid, 1-methyl-5-[4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-

d]pyrimidin-3-yl]-, methyl ester (CA INDEX NAME)




RN 482583-92-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl- (CA INDEX NAME)




RN 482584-43-0 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)- (CA INDEX NAME)



RN 482584-49-6 CAPLUS  
CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 482584-60-1 CAPLUS  
CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)-5-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 482584-67-8 CAPLUS  
CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-[(3,5-dimethyl-4-isoxazolyl)methyl]-5-methyl-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 482584-95-2 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-ylmethyl)-5-methyl-7-(2-methylpropyl)-3-(1-methyl-1H-pyrrol-2-yl)- (CA INDEX NAME)




RN 482585-01-3 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-3-[3-(1H-tetrazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 482585-68-2 CAPLUS

CN 1H-Imidazole-4-sulfonamide, 2-[2-[(5-chloro-1-(methylsulfonyl)-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 482585-73-9 CAPLUS


CN 1H-Imidazole-4-sulfonamide, 1-methyl-2-[4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




RN 482586-39-0 CAPLUS  
CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-fluorobenzo[b]thien-3-yl)methyl]-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)- (CA INDEX NAME)



RN 482586-96-9 CAPLUS  
CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(6-chloro-4-quinolinyl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482587-04-2 CAPLUS  
CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-ylmethyl)-7-(2-methylpropyl)-3-(1-methyl-1H-pyrrol-2-yl)-5-[2-(1H-pyrazol-1-yl)ethyl]- (CA INDEX NAME)



RN 482587-09-7 CAPLUS  
CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(6-chloro-4-


quinolinyl)methyl]-7-(2-methylpropyl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)-5-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 482587-14-4 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(cyclopropylmethyl)-3-[ (3R)-3-hydroxy-1-pyrrolidinyl]-5-methyl-2-(1-naphthalenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 719298-33-6 CAPLUS

CN 6H-Pyrazolo[3,4-d]pyrimidin-6-one, 4-amino-2,7-dihydro-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 719298-34-7 CAPLUS

CN 6H-Pyrazolo[3,4-d]pyrimidin-6-one, 2,7-dihydro-4-(methylamino)-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)- (CA INDEX NAME)



RN 719298-35-8 CAPLUS


CN 6H-Pyrazolo[3,4-d]pyrimidin-6-one, 4-(dimethylamino)-2,7-dihydro-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)- (CA INDEX NAME)



RN 723265-96-1 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)-2-[3-phenyl-1H-pyrazol-4-yl)methyl]-

(CA INDEX NAME)




RN 723265-99-4 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-3-(3-pyridinyl)- (CA INDEX NAME)




RN 723266-01-1 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(2,3-dichlorophenyl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)- (CA INDEX NAME)




RN 723266-03-3 CAPLUS

CN Benzoic acid, 3-[7-(cyclobutylmethyl)-4,5,6,7-tetrahydro-5-methyl-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




RN 723266-05-5 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)- (CA INDEX NAME)




RN 723266-08-8 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)-2-(4-quinolinylmethyl)- (CA INDEX NAME)




RN 723266-12-4 CAPLUS

CN 5H-Pyrazolo[3,4-d]pyrimidine-5-acetamide, 2,4,6,7-tetrahydro-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-4,6-dioxo-3-(4-pyridinyl)- (CA INDEX NAME)




RN 723266-19-1 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[2-(benzo[b]thien-3-ylmethyl)-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-, methyl ester (CA INDEX NAME)



RN 723266-22-6 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-fluoro-1H-indol-3-yl)methyl]dihydro-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)- (9CI) (CA INDEX NAME)




AB The present invention discloses crystals of glutamate racemase (MurI) from Gram-neg., Gram-pos., and atypical bacteria. The crystal lattice parameters and atomic coordinates are provided for MurI enzymes from *Helicobacter pylori*, *Escherichia coli*, *Enterococcus faecalis*, *Enterococcus faecium*, and *Staphylococcus aureus*, and with MurI enzymes complexed with activator (UDP-MurNAc-Ala) or pyrimidinedione inhibitors. Computer-assisted method for screening, identifying, and designing inhibitors of MurI with MIC values of  $\leq 8 \mu\text{g/mL}$  and Kd of  $\leq 1 \mu\text{M}$  and their use for treatment of bacterial infections are provided./.

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2004:546511 CAPLUS  
 DOCUMENT NUMBER: 141:106488  
 TITLE: Preparation of pyrazolo[3,4-d]pyrimidine derivatives  
 for treatment of H.pylori infection  
 INVENTOR(S): Basarab, Gregory; Eyermann, Joseph; Gowravaram,  
 Madhusudhan; Green, Oluyinka; Macpherson, Lawrence;  
 Morningstar, Marshall; Nguyen, Thanh  
 PATENT ASSIGNEE(S): AstraZeneca Ab, Swed.  
 SOURCE: PCT Int. Appl., 129 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056831	A1	20040708	WO 2003-SE2033	20031219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003288869	A1	20040714	AU 2003-288869	20031219
EP 1585748	A1	20051019	EP 2003-781250	20031219
EP 1585748	B1	20061227		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006512366	T	20060413	JP 2004-562221	20031219
AT 349448	T	20070115	AT 2003-781250	20031219
ES 2278211	T3	20070801	ES 2003-781250	20031219
US 20070004761	A1	20070104	US 2006-539936	20060505
PRIORITY APPLN. INFO.:			SE 2002-3825	A 20021220
			WO 2003-SE2033	W 20031219

OTHER SOURCE(S): MARPAT 141:106488  
 IT 719298-23-4P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic  
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
 (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (drug candidate; preparation of pyrazolo[3,4-d]pyrimidine derivs. for  
 treatment of H.pylori infection)  
 RN 719298-23-4 CAPLUS  
 CN 1H-Pyrrole-3-carbonitrile, 5-[4-amino-2-[(6-chloro-4-quinolinyl)methyl]-  
 6,7-dihydro-7-(2-methylpropyl)-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-  
 methyl- (CA INDEX NAME)




IT 719298-19-8P 719298-20-1P 719298-21-2P  
 719298-22-3P 719298-24-5P 719298-25-6P  
 719298-26-7P 719298-27-8P 719298-28-9P  
 719298-29-0P 719298-30-3P 719298-31-4P  
 719298-33-6P 719298-34-7P 719298-35-8P  
 719298-37-0P 719298-38-1P 719298-39-2P  
 719298-40-5P 719298-41-6P 719298-42-7P  
 719298-43-8P 719298-44-9P 719298-45-0P  
 719298-46-1P 719298-47-2P 719298-50-7P  
 719298-51-8P 719298-52-9P 719298-53-0P  
 719298-54-1P 719298-55-2P 719298-56-3P  
 719298-57-4P 719298-58-5P 719298-59-6P  
 719298-60-9P 719298-61-0P 719298-62-1P  
 719298-64-3P 719298-65-4P 719298-66-5P  
 719298-67-6P 719298-68-7P 719298-69-8P  
 719298-70-1P 719298-71-2P 719298-73-4P  
 719298-74-5P 719300-37-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of pyrazolo[3,4-d]pyrimidine derivs. for treatment of H.pylori infection)

RN 719298-19-8 CAPLUS


CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-6,7-dihydro-4-[(2-hydroxyethyl)amino]-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-20-1 CAPLUS  
CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-6,7-dihydro-4-[(2-hydroxypropyl)amino]-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)



RN 719298-21-2 CAPLUS  
CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-6,7-dihydro-4-[(2-hydroxy-1-methylethyl)amino]-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-22-3 CAPLUS  
CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-6,7-dihydro-4-[(3-hydroxypropyl)amino]-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-24-5 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-6,7-dihydro-4-(methylamino)-7-(2-methylpropyl)-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-25-6 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-4-(dimethylamino)-6,7-dihydro-7-(2-methylpropyl)-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-26-7 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-6,7-dihydro-7-(2-methylpropyl)-6-oxo-4-(propylamino)-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-27-8 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-6,7-dihydro-4-(hydroxyamino)-7-(2-methylpropyl)-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-28-9 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-4-(cyclopropylamino)-6,7-dihydro-7-(2-methylpropyl)-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-29-0 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-6,7-dihydro-4-[(2-hydroxyethyl)amino]-7-(2-methylpropyl)-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-30-3 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-4-hydrazino-6,7-dihydro-7-(2-methylpropyl)-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (9CI) (CA INDEX NAME)




RN 719298-31-4 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-4-(2,2-dimethylhydrazino)-6,7-dihydro-7-(2-methylpropyl)-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (9CI) (CA INDEX NAME)



RN 719298-33-6 CAPLUS


CN 6H-Pyrazolo[3,4-d]pyrimidin-6-one, 4-amino-2,7-dihydro-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)- (CA INDEX NAME)



RN 719298-34-7 CAPLUS


CN 6H-Pyrazolo[3,4-d]pyrimidin-6-one, 2,7-dihydro-4-(methylamino)-7-(2-

methylpropyl)-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 719298-35-8 CAPLUS

CN 6H-Pyrazolo[3,4-d]pyrimidin-6-one, 4-(dimethylamino)-2,7-dihydro-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 719298-37-0 CAPLUS

CN 6H-Pyrazolo[3,4-d]pyrimidin-6-one, 4-amino-2-[(6-chloro-4-quinolinyl)methyl]-2,7-dihydro-7-(2-methylpropyl)-3-(1-methyl-1H-pyrrol-2-yl)- (CA INDEX NAME)




RN 719298-38-1 CAPLUS

CN Acetamide, N-[2-[(6-chloro-4-quinolinyl)methyl]-3-(4-cyano-1-methyl-1H-pyrrol-2-yl)-6,7-dihydro-7-(2-methylpropyl)-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-4-yl]- (CA INDEX NAME)




RN 719298-39-2 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-6-oxo-4-thioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-40-5 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-6,7-dihydro-4-(methylthio)-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-41-6 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)



RN 719298-42-7 CAPLUS


CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4-hydrazino-6,7-dihydro-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (9CI) (CA INDEX NAME)



RN 719298-43-8 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-6,7-dihydro-4-[(2S)-2-hydroxypropyl]amino]-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 719298-44-9 CAPLUS


CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-6,7-dihydro-4-[(2R)-2-hydroxypropyl]amino]-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 719298-45-0 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[6-amino-2-[(6-chloro-4-quinolinyl)methyl]-4,5-dihydro-5-methyl-4-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-46-1 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-6-imino-5-methyl-4-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-47-2 CAPLUS

CN Butanamide, N-[2-[(6-chloro-4-quinolinyl)methyl]-3-(4-cyano-1-methyl-1H-pyrrol-2-yl)-4,5-dihydro-5-methyl-4-oxo-2H-pyrazolo[3,4-d]pyrimidin-6-yl]-3-methyl- (CA INDEX NAME)



RN 719298-50-7 CAPLUS


CN 1H-Pyrrole-3-carbonitrile, 5-[4-amino-2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-6,7-dihydro-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-51-8 CAPLUS

CN 6H-Pyrazolo[3,4-d]pyrimidin-6-one, 2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-2,4,5,7-tetrahydro-5-methyl-3-(1-methyl-1H-imidazol-5-yl)-4-thioxo- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 719298-52-9 CAPLUS


CN 6H-Pyrazolo[3,4-d]pyrimidin-6-one, 2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-2,4,5,7-tetrahydro-5-methyl-3-(1-methyl-1H-imidazol-5-yl)-4-(methylimino)-(4Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 719298-53-0 CAPLUS


CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-4-imino-5-methyl-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)



RN 719298-54-1 CAPLUS


CN 1H-Pyrrole-3-carbonitrile, 5-[(4Z)-2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4-(methylimino)-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 719298-55-2 CAPLUS


CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4-oxo-6-thioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)



RN 719298-56-3 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[(6Z)-2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-6-(methylimino)-4-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 719298-57-4 CAPLUS

CN Acetamide, N-[2-[(6-chloro-4-quinolinyl)methyl]-3-(4-cyano-1-methyl-1H-pyrrol-2-yl)-7-(cyclopropylmethyl)-2,4,5,7-tetrahydro-5-methyl-4-oxo-6H-pyrazolo[3,4-d]pyrimidin-6-ylidene]-, [N(Z)]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 719298-58-5 CAPLUS

CN Methanesulfonamide, N-[2-[(6-chloro-4-quinolinyl)methyl]-3-(4-cyano-1-methyl-1H-pyrrol-2-yl)-7-(cyclopropylmethyl)-2,4,5,7-tetrahydro-5-methyl-4-oxo-6H-pyrazolo[3,4-d]pyrimidin-6-ylidene]-, [N(Z)]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 719298-59-6 CAPLUS


CN 1H-Pyrrole-3-carbonitrile, 5-[{(6Z)-2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-6-[[2-(dimethylamino)ethyl]imino]-4,5,6,7-tetrahydro-5-methyl-4-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl}-1-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 719298-60-9 CAPLUS

CN Acetamide, N-[2-[(6-chloro-4-quinolinyl)methyl]-3-(4-cyano-1-methyl-1H-pyrrol-2-yl)-7-(cyclopropylmethyl)-2,4,5,7-tetrahydro-5-methyl-4-oxo-6H-pyrazolo[3,4-d]pyrimidin-6-ylidene]-2-(dimethylamino)- (CA INDEX NAME)




RN 719298-61-0 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-62-1 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-6,7-dihydro-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-64-3 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-6-[(cyclopropylmethyl)amino]-4,5-dihydro-5-methyl-4-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-65-4 CAPLUS

CN 1-Propanesulfonamide, N-[2-[(6-chloro-4-quinolinyl)methyl]-3-(4-cyano-1-methyl-1H-pyrrol-2-yl)-4,5-dihydro-5-methyl-4-oxo-2H-pyrazolo[3,4-d]pyrimidin-6-yl]- (CA INDEX NAME)




RN 719298-66-5 CAPLUS

CN Carbamic acid, [2-[(6-chloro-4-quinolinyl)methyl]-3-(4-cyano-1-methyl-1H-pyrrol-2-yl)-4,5-dihydro-5-methyl-4-oxo-2H-pyrazolo[3,4-d]pyrimidin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 719298-67-6 CAPLUS


CN Urea, N-[2-[(6-chloro-4-quinolinyl)methyl]-3-(4-cyano-1-methyl-1H-pyrrol-2-yl)-4,5-dihydro-5-methyl-4-oxo-2H-pyrazolo[3,4-d]pyrimidin-6-yl]-N'-ethyl- (CA INDEX NAME)



RN 719298-68-7 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[(4Z)-2-[(6-chloro-4-quinolinyl)methyl]-6-[(cyclopropylmethyl)amino]-4,5-dihydro-5-methyl-4-(methylimino)-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 719298-69-8 CAPLUS


CN 1H-Pyrrole-3-carbonitrile, 5-[(4Z,6Z)-2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-bis(methylimino)-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 719298-70-1 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-6,7-dihydro-4-[(2-hydroxybutyl)amino]-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-71-2 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-6,7-dihydro-4-methoxy-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-73-4 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[6-chloro-4-(cyclopropylmethyl)amino]-4-(methoxymethyl)-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-74-5 CAPLUS

CN Cyclopropaneacetamide, N-[3-(4-acetyl-1-methyl-1H-pyrrol-2-yl)-2-[6-chloro-4-(cyclopropylmethyl)amino]-4-methoxy-2H-pyrazolo[3,4-d]pyrimidin-6-yl]- (CA INDEX NAME)




RN 719300-37-5 CAPLUS


CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4,7-dihydro-6-(methylamino)-4-(methylimino)-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (9CI) (CA INDEX NAME)



IT 719298-78-9P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (intermediate; preparation of pyrazolo[3,4-d]pyrimidine derivs. for treatment of H.pylori infection)  
 RN 719298-78-9 CAPLUS  
 CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




IT 482583-68-6, 7-Isobutyl-2-(1-naphthylmethyl)-3-pyridin-4-yl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482587-30-4,  
 5-[2-[(6-Chloroquinolin-4-yl)methyl]-7-isobutyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carbonitrile  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of pyrazolo[3,4-d]pyrimidine derivs. for treatment of H.pylori infection)  
 RN 482583-68-6 CAPLUS  
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)- (CA INDEX NAME)



RN 482587-30-4 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-4,5,6,7-tetrahydro-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)



GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The title compds. I-IV [wherein X = S, O, or NR20, with exclusions; W = S, O, or NR20, with an exclusion; R1 = H, (un)substituted alkyl, alkenyl, etc.; R2 = H, (un)substituted alkyl, alkenyl, etc.; R3 = (hetero)cyclyl; R4 = (hetero)cyclyl; R20 = H, CN, (un)substituted alkyl, etc.] or pharmaceutically acceptable salts thereof are prepared for the treatment or prophylaxis of *H. pylori* infection. For example, the compound V was prepared in a multi-step synthesis. These compds. showed IC50 of <400 μM against glutamate racemase.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2003:22881 CAPLUS  
 DOCUMENT NUMBER: 138:89821  
 TITLE: Preparation of pyrazolo[3,4-d]pyrimidines for inhibiting H. pylori infections  
 INVENTOR(S): Basarab, Gregory; Eyermann, Joseph; Gowravaram, Madhusudhan; Green, Oluyinka; MacPherson, Lawrence; Morningstar, Marshall; Nguyen, Thanh  
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.  
 SOURCE: PCT Int. Appl., 240 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003002567	A1	20030109	WO 2002-SE1303	20020628
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002315992	A1	20030303	AU 2002-315992	20020628
EP 1412355	A1	20040428	EP 2002-746256	20020628
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004521944	T	20040722	JP 2003-508948	20020628
US 20040254183	A1	20041216	US 2004-481178	20040614
US 7285558	B2	20071023		
PRIORITY APPLN. INFO.:			SE 2001-2315	A 20010628
			WO 2002-SE1303	W 20020628

OTHER SOURCE(S): MARPAT 138:89821  
 IT 482583-70-0P, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carboxylic acid 482583-73-3P  
 482583-86-8P, 5-[7-(Cyclopropylmethyl)-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carboxylic acid  
 482583-87-9P, 5-[2-[(5-Chloro-1H-indazol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carboxylic acid  
 482583-88-0P, 5-[7-Isobutyl-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carboxylic acid 482583-89-1P,  
 5-[2-[(6-Chloroquinolin-4-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carboxylic acid 482583-90-4P, 5-[2-(1-Benzothien-3-ylmethyl)-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carboxylic acid 482584-39-4P,  
 2-[(5-Chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-[1-methyl-4-(trifluoroacetyl)-1H-pyrrol-2-yl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-56-5P, 2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-3-(1-methyl-1H-imidazol-2-yl)-2H-pyrazolo[3,4-


d]pyrimidine-4,6(5H,7H)-dione 482584-70-3P, 3-[7-Isobutyl-5-methyl-2-[(naphth-1-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]benzoic acid 482584-98-5P, 5-Methyl-2-[(naphth-1-yl)methyl]-3-(4-pyridinyl)-7-[(trifluoromethyl)sulfanyl]methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482585-00-2P, 5-Methyl-7-[(methylthio)methyl]-2-[(naphth-1-yl)methyl]-3-(pyridin-4-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482585-01-3P, 7-Isobutyl-5-methyl-2-[(naphth-1-yl)methyl]-3-[3-(1H-1,2,3,4-tetrazol-5-yl)phenyl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482585-02-4P 482585-47-7P, N-(tert-Butyl)-2-[7-isobutyl-5-methyl-2-[(naphth-1-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-imidazole-4-sulfonamide 482585-53-5P, N-(tert-Butyl)-3-[7-isobutyl-5-methyl-2-[(naphth-1-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]benzenesulfonamide 482585-71-7P, N-(tert-Butyl)-2-[7-isobutyl-5-methyl-2-[(naphth-1-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl-1H-imidazole-4-sulfonamide 482585-72-8P, N-(tert-Butyl)-3-[7-isobutyl-5-methyl-2-[(naphth-1-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-methylbenzenesulfonamide 482585-74-0P, 2-[7-Isobutyl-5-methyl-2-[(naphth-1-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-imidazole-4-sulfonamide trifluoroacetate (1:1) 482585-75-1P, 3-[7-Isobutyl-5-methyl-2-[(naphth-1-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]benzenesulfonamide 482587-08-6P, 2-[(6-Chloroquinolin-4-yl)methyl]-7-isobutyl-3-(4-methyl-4H-1,2,4-triazol-3-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(antibacterial agent; preparation of pyrazolo[3,4-d]pyrimidine H. pylori antibacterial agents by cyclocondensation of pyrimidinylhydrazones with aldehydes)


RN 482583-70-0 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 482583-73-3 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(3-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 482583-86-8 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 482583-87-9 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[2-[(5-chloro-1H-indazol-3-yl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 482583-88-0 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 1-methyl-5-[4,5,6,7-tetrahydro-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




RN 482583-89-1 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[2-[(6-chloro-4-quinolinyl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 482583-90-4 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 2-[2-(benzo[b]thien-3-ylmethyl)-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 482584-39-4 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-[1-methyl-4-(trifluoroacetyl)-1H-pyrrol-2-yl]- (9CI) (CA INDEX NAME)




RN 482584-56-5 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482584-70-3 CAPLUS  
CN Benzoic acid, 3-[4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)



RN 482584-98-5 CAPLUS  
CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)-7-[(trifluoromethyl)thio]methyl- (CA INDEX NAME)




RN 482585-00-2 CAPLUS  
CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-7-[(methylthio)methyl]-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 482585-01-3 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-3-[3-(1H-tetrazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 482585-02-4 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-2-(1-naphthalenylmethyl)-7-[(phenylthio)methyl]-3-(4-pyridinyl)- (CA INDEX NAME)




RN 482585-47-7 CAPLUS

CN 1H-Imidazole-4-sulfonamide, N-(1,1-dimethylethyl)-1-methyl-2-[4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




RN 482585-53-5 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




RN 482585-71-7 CAPLUS

CN 1H-Imidazole-4-sulfonamide, N-(1,1-dimethylethyl)-N,1-dimethyl-2-[4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)



RN 482585-72-8 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-N-methyl-3-[4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




RN 482585-74-0 CAPLUS

CN 1H-Imidazole-4-sulfonamide, 1-methyl-2-[4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 482585-73-9

CMF C25 H27 N7 O4 S




CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 482585-75-1 CAPLUS  
CN Benzenesulfonamide, 3-[4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)



RN 482587-08-6 CAPLUS  
CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(6-chloro-4-quinolinyl)methyl]-7-(2-methylpropyl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)- (CA INDEX NAME)



IT 482583-54-0P, N-[4-[7-Isobutyl-5-methyl-2-[(naphth-1-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]acetamide 482583-56-2P, 7-Isobutyl-5-methyl-3-(3-methylthien-2-yl)-2-[(naphth-1-yl)methyl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482583-57-3P, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carbonitrile 482583-59-5P, 5-Methyl-7-(2-methylbenzyl)-2-[(naphth-1-yl)methyl]-3-(pyridin-4-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482583-63-1P, 3-[7-[(3,5-Dimethylisoxazol-4-yl)methyl]-5-methyl-2-[(naphth-1-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]benzoic acid 482583-64-2P, 7-Isobutyl-5-(2-(morpholin-4-yl)ethyl)-2-[(naphth-1-yl)methyl]-3-(pyridin-4-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482583-69-7P, Methyl 5-[7-isobutyl-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carboxylate 482583-72-2P, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-[2-(dimethylamino)ethyl]-1-methyl-1H-pyrrole-3-carboxamide 482583-76-6P, 2-[(6-Chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-[1-methyl-4-(1H-tetrazol-5-yl)-1H-pyrrol-2-yl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482583-77-7P, Methyl 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carboxylate 482583-78-8P, Methyl 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carboxylate 482583-79-9P, Methyl 5-[2-(1-benzothien-3-ylmethyl)-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carboxylate 482583-80-2P, Methyl 5-[7-isobutyl-5-methyl-2-[(naphth-1-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carboxylate 482583-81-3P, Methyl 5-[2-[(5-chloro-2-methyl-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carboxylate 482583-82-4P, Methyl 5-[2-[(6-chloroquinolin-4-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carboxylate 482583-83-5P, Methyl 5-[2-[(5-fluoro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carboxylate 482583-84-6P, Methyl 5-[2-[(5-cyano-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carboxylate

482583-85-7P, Methyl 5-[7-(cyclopropylmethyl)-2-[(5-ethyl-1H-indol-3-yl)methyl]-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carboxylate 482583-91-5P  
, 5-[2-[(5-Chloro-1H-indazol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carboxylic acid 482583-92-6P, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl-1H-pyrrole-3-carboxamide 482583-93-7P, N-Cyclopropyl-5-[7-(cyclopropylmethyl)-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carboxamide 482583-94-8P, 5-[7-(Cyclopropylmethyl)-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-methoxy-1-methyl-1H-pyrrole-3-carboxamide 482583-95-9P 482583-97-1P, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-methoxy-1-methyl-1H-pyrrole-3-carboxamide 482583-98-2P, 5-[7-(Cyclopropylmethyl)-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl-1H-pyrrole-3-carboxamide 482583-99-3P, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-[2-(dimethylamino)ethyl]-1-methyl-1H-pyrrole-3-carboxamide 482584-00-9P, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-cyclopropyl-1-methyl-1H-pyrrole-3-carboxamide 482584-01-0P, 5-[2-[(6-Chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-methoxy-1-methyl-1H-pyrrole-3-carboxamide 482584-03-2P, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-N-[3-(4-methylpiperazin-1-yl)propyl]-1H-pyrrole-3-carboxamide 482584-04-3P, N-(2-Aminoethyl)-5-[2-[(5-chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carboxamide 482584-05-4P, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-[3-(1H-imidazol-1-yl)propyl]-1-methyl-1H-pyrrole-3-carboxamide 482584-07-6P, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-(2-hydroxyethyl)-1-methyl-1H-pyrrole-3-carboxamide 482584-08-7P, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-N-(2-morpholin-4-yl)ethyl]-1H-pyrrole-3-carboxamide 482584-09-8P, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-N-[2-(methylsulfonyl)ethyl]-1H-pyrrole-3-carboxamide 482584-10-1P, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-methoxy-1-methyl-1H-pyrrole-3-carboxamide 482584-11-2P, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-(2-methoxyethyl)-1-methyl-1H-pyrrole-3-carboxamide 482584-12-3P, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-N-(pyridin-4-ylmethyl)-1H-pyrrole-3-carboxamide 482584-13-4P, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-

methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-[2-(isopropylamino)ethyl]-1-methyl-1H-pyrrole-3-carboxamide  
482584-14-5P, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carboxamide 482584-15-6P,  
5-[2-[(6-Chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-cyclopropyl-1-methyl-1H-pyrrole-3-carboxamide 482584-16-7P,  
5-[2-[(6-Chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-[2-(dimethylamino)ethyl]-1-methyl-1H-pyrrole-3-carboxamide  
482584-17-8P, 5-[2-[(6-Chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-[2-(dimethylamino)ethyl]-1-methyl-1H-pyrrole-3-carboxamide  
482584-18-9P, N-Cyclopropyl-5-[7-isobutyl-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carboxamide 482584-19-0P  
, 5-[7-Isobutyl-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-methoxy-1-methyl-1H-pyrrole-3-carboxamide 482584-20-3P, 5-[7-Isobutyl-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl-1H-pyrrole-3-carboxamide  
482584-21-4P, 5-[2-[(5-Chloro-1H-indazol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl-1H-pyrrole-3-carboxamide  
482584-22-5P, 5-[2-[(5-Chloro-1H-indazol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-cyclopropyl-1-methyl-1H-pyrrole-3-carboxamide  
482584-23-6P, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-N-1H-1,2,4-triazol-3-yl-1H-pyrrole-3-carboxamide  
482584-24-7P, 5-[2-[(6-Chloroquinolin-4-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-cyclopropyl-1-methyl-1H-pyrrole-3-carboxamide 482584-25-8P,  
5-[2-[(6-Chloroquinolin-4-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-methoxy-1-methyl-1H-pyrrole-3-carboxamide 482584-26-9P, 5-[2-[(6-Chloroquinolin-4-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl-1H-pyrrole-3-carboxamide  
482584-27-0P, 5-[2-(1-Benzothien-3-ylmethyl)-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-[2-(dimethylamino)ethyl]-1-methyl-1H-pyrrole-3-carboxamide  
482584-28-1P, 5-[2-(1-Benzothien-3-ylmethyl)-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl-1H-pyrrole-3-carboxamide 482584-29-2P,  
N-[2-(Dimethylamino)ethyl]-5-[7-isobutyl-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carboxamide 482584-30-5P,  
2-(Dimethylamino)ethyl 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carboxylate 482584-31-6P,  
5-[2-[(6-Chloroquinolin-4-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-[2-(dimethylamino)ethyl]-1-methyl-1H-pyrrole-3-carboxamide 482584-32-7P,  
2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-3-[1-methyl-4-(piperazin-1-ylcarbonyl)-1H-pyrrol-2-yl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-33-8P, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,N,1-trimethyl-1H-pyrrole-3-carboxamide

482584-34-9P, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carbonitrile 482584-35-0P  
, 5-[7-(Cyclopropylmethyl)-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carbonitrile 482584-36-1P, 5-[7-Isobutyl-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carbonitrile 482584-37-2P, 3-(4-Acetyl-1-methyl-1H-pyrrol-2-yl)-2-[(5-chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-38-3P, 3-(4-Acetyl-1-methyl-1H-pyrrol-2-yl)-2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-41-8P  
, 5-Methyl-2-[(naphth-1-yl)methyl]-7-neopentyl-3-(pyridin-4-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-42-9P,  
5-[2-[(5-Chloro-1H-indazol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carbonitrile 482584-43-0P, 2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-44-1P,  
7-Isobutyl-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2-[(5-nitro-1H-indol-3-yl)methyl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-45-2P, 2-[(5-Chloro-2-methyl-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-46-3P, 7-Isobutyl-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2-[(5-methyl-1H-indol-3-yl)methyl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-47-4P,  
7-Isobutyl-5-methyl-3-(1-methyl-1H-pyrrol-2-yl)-2-[(naphth-1-yl)methyl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-48-5P,  
5-[7-Isobutyl-5-methyl-2-[(2-methyl-1H-indol-3-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carbonitrile 482584-49-6P, 7-Isobutyl-5-methyl-2-[(naphth-1-yl)methyl]-3-(pyridin-4-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-50-9P, 2-(1-Benzothien-3-ylmethyl)-7-isobutyl-5-methyl-3-(3-methylthien-2-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-51-0P, 3-[(7-Isobutyl-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]-1H-indole-5-carbonitrile 482584-52-1P, 7-Isobutyl-2-[(5-methoxy-1H-indol-3-yl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-53-2P,  
7-Isobutyl-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2-[(4-methyl-1H-indol-3-yl)methyl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-54-3P, 7-Isobutyl-5-methyl-2-[(naphth-1-yl)methyl]-3-thien-2-yl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-55-4P,  
2-(1-Benzothien-3-ylmethyl)-7-isobutyl-5-methyl-3-(pyridin-4-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-57-6P,  
2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-3-(1-methyl-1H-imidazol-2-yl)-5-(2-(morpholin-4-yl)ethyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-58-7P, 2-[(5-Chloro-1H-indol-3-yl)methyl]-5-(2-hydroxyethyl)-7-isobutyl-3-(1-methyl-1H-imidazol-2-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-59-8P,  
7-Isobutyl-2-[(naphth-1-yl)methyl]-3-(pyridin-4-yl)-5-(pyridin-3-ylmethyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-60-1P,  
7-Isobutyl-2-[(naphth-1-yl)methyl]-3-(pyridin-4-yl)-5-(pyridin-4-ylmethyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-61-2P,  
2-[(5-Chloro-1H-indol-3-yl)methyl]-5-methyl-7-(3-methylbutyl)-3-(1-methyl-1H-imidazol-2-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-62-3P, 2-[(5-Chloro-1H-indol-3-yl)methyl]-7-(cyclobutylmethyl)-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2H-pyrazolo[3,4-

d]pyrimidine-4,6(5H,7H)-dione 482584-64-5P, 2-[(5-Chloro-1H-indol-3-yl)methyl]-7-[(3,5-dimethylisoxazol-4-yl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-65-6P, 2-[(5-Chloro-1H-indol-3-yl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-propyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-66-7P, 2-[(5-Chloro-1H-indol-3-yl)methyl]-5-methyl-7-(2-methylbenzyl)-3-(1-methyl-1H-imidazol-2-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-67-8P, 7-[(3,5-Dimethylisoxazol-4-yl)methyl]-5-methyl-2-[(naphth-1-yl)methyl]-3-(pyridin-4-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-68-9P, 7-(4-Hydroxybenzyl)-5-methyl-2-[(naphth-1-yl)methyl]-3-(pyridin-4-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-69-0P, 3-[(5-Methyl-2-[(naphth-1-yl)methyl]-4,6-dioxo-3-(pyridin-4-yl)-2,4,5,6-tetrahydro-7H-pyrazolo[3,4-d]pyrimidin-7-yl)methyl]benzoic acid 482584-71-4P, 3-[(7-Isobutyl-5-methyl-2-[(naphth-1-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl)benzamide 482584-72-5P, 3-[(5-Methyl-7-(3-methylbutyl)-2-[(naphth-1-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl)benzoic acid 482584-74-7P, 3-[(7-(Cyclopropylmethyl)-5-methyl-2-[(naphth-1-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl)benzoic acid 482584-75-8P, 3-(4-Amino-1-methyl-1H-imidazol-2-yl)-2-(benzothien-3-ylmethyl)-7-isobutyl-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-77-0P, N-[2-[(2-(Benzothien-3-ylmethyl)-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl)-1-methyl-1H-imidazol-4-yl]acetamide 482584-79-2P, tert-Butyl [2-[(2-[(5-chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl)-1-methyl-1H-imidazol-4-yl]carbamate 482584-80-5P, 3-(4-Amino-1-methyl-1H-imidazol-2-yl)-2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-81-6P, 3-(2-Amino-5-methyl-1,3-thiazol-4-yl)-2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-83-8P, 3-(2-Amino-4-methyl-1,3-thiazol-5-yl)-2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-85-0P, 3-(2-Amino-4-methyl-1,3-thiazol-5-yl)-2-[(5-chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-87-2P, 3-(2-Amino-5-methyl-1,3-thiazol-4-yl)-2-[(5-chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-89-4P, tert-Butyl [4-[(2-[(5-chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl)-5-methylthiazol-2-yl]carbamate 482584-90-7P, 3-(2-Amino-5-methyl-1,3-thiazol-4-yl)-2-(benzothien-3-ylmethyl)-7-isobutyl-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-91-8P, N-[4-[(2-(Benzothien-3-ylmethyl)-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl)-5-methyl-1,3-thiazol-2-yl]acetamide 482584-93-0P, 2-[(5-Chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-[1-methyl-4-((1Z)-2,2,2-trifluoro-N-hydroxyethanimidoyl)-1H-pyrrol-2-yl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-95-2P, 2-(Benzothiophen-3-ylmethyl)-7-isobutyl-5-methyl-3-(1-methyl-1H-pyrrol-2-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-96-3P, 5-Methyl-2-[(naphth-1-yl)methyl]-3-(4-pyridinyl)-7-[(trifluoromethyl)sulfinyl)methyl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-97-4P, 5-Methyl-2-[(naphth-1-yl)methyl]-3-(4-pyridinyl)-7-[(trifluoromethyl)sulfonyl)methyl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-99-6P, 5-Methyl-7-[(methylsulfinyl)methyl]-2-[(naphth-1-yl)methyl]-3-(pyridin-4-yl)-2H-

pyrazolo[3, 4-d]pyrimidine-4, 6(5H, 7H)-dione 482585-03-5P,  
5-Methyl-2-[(naphth-1-yl)methyl]-7-[(phenylsulfinyl)methyl]-3-(pyridin-4-  
yl)-2H-pyrazolo[3, 4-d]pyrimidine-4, 6(5H, 7H)-dione 482585-05-7P  
, 2-[5-Methyl-2-[(naphth-1-yl)methyl]-4, 6-dioxo-3-(4-pyridinyl)-2, 4, 5, 6-  
tetrahydro-7H-pyrazolo[3, 4-d]pyrimidin-7-yl]butanenitrile  
482585-06-8P, 2-(1-Benzothiophen-3-ylmethyl)-3-(2-fluorophenyl)-7-  
isobutyl-5-methyl-2H-pyrazolo[3, 4-d]pyrimidine-4, 6(5H, 7H)-dione  
482585-07-9P, 3-(3-Furyl)-7-isobutyl-5-methyl-2-[(naphth-1-  
yl)methyl]-2H-pyrazolo[3, 4-d]pyrimidine-4, 6(5H, 7H)-dione  
482585-08-0P, 2-(2, 3-Dichlorobenzyl)-3-(3-furyl)-7-isobutyl-5-  
methyl-2H-pyrazolo[3, 4-d]pyrimidine-4, 6(5H, 7H)-dione 482585-09-1P  
, 2-(Benzothien-3-ylmethyl)-3-(3-furyl)-7-isobutyl-5-methyl-2H-  
pyrazolo[3, 4-d]pyrimidine-4, 6(5H, 7H)-dione 482585-10-4P,  
2-(3-Bromobenzyl)-7-isobutyl-5-methyl-3-(pyridin-4-yl)-2H-pyrazolo[3, 4-  
d]pyrimidine-4, 6(5H, 7H)-dione 482585-11-5P, 3-[(7-Isobutyl-5-  
methyl-4, 6-dioxo-3-(pyridin-4-yl)-4, 5, 6, 7-tetrahydro-2H-pyrazolo[3, 4-  
d]pyrimidin-2-yl)methyl]benzonitrile 482585-12-6P,  
2-(3-Iodobenzyl)-7-isobutyl-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2H-  
pyrazolo[3, 4-d]pyrimidine-4, 6(5H, 7H)-dione 482585-13-7P,  
7-Allyl-5-methyl-2-[(naphth-1-yl)methyl]-3-(4-pyridinyl)-2H-pyrazolo[3, 4-  
d]pyrimidine-4, 6(5H, 7H)-dione 482585-15-9P, 7-[2-  
(Dimethylamino)ethyl]-5-methyl-2-[(naphth-1-yl)methyl]-3-(4-pyridinyl)-2H-  
pyrazolo[3, 4-d]pyrimidine-4, 6(5H, 7H)-dione 482585-16-0P,  
3-[7-(2-Chlorobenzyl)-5-methyl-2-[(naphth-1-yl)methyl]-4, 6-dioxo-4, 5, 6, 7-  
tetrahydro-2H-pyrazolo[3, 4-d]pyrimidin-3-yl]benzoic acid  
482585-17-1P, 3-[7-Isobutyl-5-methyl-2-[(naphth-1-yl)methyl]-4, 6-  
dioxo-4, 5, 6, 7-tetrahydro-2H-pyrazolo[3, 4-d]pyrimidin-3-yl]-N-  
methylbenzamide 482585-38-6P, 5-Methyl-2-[(naphth-1-yl)methyl]-3-  
(pyridin-4-yl)-7-(2, 2, 2-trifluoroethyl)-2H-pyrazolo[3, 4-d]pyrimidine-  
4, 6(5H, 7H)-dione trifluoroacetate (1:1) 482585-40-0P,  
5-Methyl-3-(1-methyl-1H-imidazol-2-yl)-2-[(naphth-1-yl)methyl]-7-(2, 2, 2-  
trifluoroethyl)-2H-pyrazolo[3, 4-d]pyrimidine-4, 6(5H, 7H)-dione  
482585-41-1P, 7-(3-Fluoropropyl)-5-methyl-3-(1-methyl-1H-imidazol-  
2-yl)-2-[(naphth-1-yl)methyl]-2H-pyrazolo[3, 4-d]pyrimidine-4, 6(5H, 7H)-  
dione 482585-42-2P, 2-(Benzothien-3-ylmethyl)-7-(3-fluoropropyl)-  
5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2H-pyrazolo[3, 4-d]pyrimidine-  
4, 6(5H, 7H)-dione 482585-43-3P, 2-(Benzothien-3-ylmethyl)-5-  
methyl-3-(1-methyl-1H-imidazol-2-yl)-7-propyl-2H-pyrazolo[3, 4-d]pyrimidine-  
4, 6(5H, 7H)-dione 482585-44-4P, 2-(Benzothien-3-ylmethyl)-5-  
methyl-3-(1-methyl-1H-imidazol-2-yl)-7-(2, 2, 2-trifluoroethyl)-2H-  
pyrazolo[3, 4-d]pyrimidine-4, 6(5H, 7H)-dione 482585-45-5P,  
2-(Benzothien-3-ylmethyl)-5-methyl-3-(pyridin-4-yl)-7-(2, 2, 2-  
trifluoroethyl)-2H-pyrazolo[3, 4-d]pyrimidine-4, 6(5H, 7H)-dione  
482585-46-6P, 5-Methyl-3-(1-methyl-1H-imidazol-2-yl)-2-(1-  
naphthalenylmethyl)-7-propyl-2H-pyrazolo[3, 4-d]pyrimidine-4, 6(5H, 7H)-dione  
482585-54-6P, N-(tert-Butyl)-2-[2-[(5-chloro-1H-indol-3-yl)methyl]-  
7-isobutyl-5-methyl-4, 6-dioxo-4, 5, 6, 7-tetrahydro-2H-pyrazolo[3, 4-  
d]pyrimidin-3-yl]-1-methyl-1H-imidazole-4-sulfonamide 482585-55-7P  
, 2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-3-(1-methyl-1H-  
imidazol-5-yl)-2H-pyrazolo[3, 4-d]pyrimidine-4, 6(5H, 7H)-dione  
482585-56-8P, 7-Isobutyl-5-methyl-3-(1-methyl-1H-imidazol-5-yl)-2-  
[(naphth-1-yl)methyl]-2H-pyrazolo[3, 4-d]pyrimidine-4, 6(5H, 7H)-dione  
482585-57-9P, 2-[(5-Chloro-1H-indol-3-yl)methyl]-3-(1, 3-dimethyl-2-  
thioxo-2, 3-dihydro-1H-imidazol-4-yl)-7-isobutyl-5-methyl-2H-pyrazolo[3, 4-  
d]pyrimidine-4, 6(5H, 7H)-dione 482585-58-0P, 3-[2-[(5-Fluoro-  
3a, 7a-dihydro-1-benzothien-3-yl)methyl]-7-isobutyl-5-methyl-4, 6-dioxo-  
4, 5, 6, 7-tetrahydro-2H-pyrazolo[3, 4-d]pyrimidin-3-yl]benzenesulfonamide  
482585-59-1P, 3-[7-Isobutyl-5-methyl-2-[(5-methyl-3a, 7a-dihydro-1H-  
indol-3-yl)methyl]-4, 6-dioxo-4, 5, 6, 7-tetrahydro-2H-pyrazolo[3, 4-

d]pyrimidin-3-yl]benzenesulfonamide 482585-60-4P,  
3-[2-[(5-Chloro-3a,7a-dihydro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-  
4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-  
y1]benzenesulfonamide 482585-61-5P, 2-[(5-Fluorobenzothien-3-  
y1)methyl]-7-isobutyl-5-methyl-3-(1-methyl-1H-imidazol-5-yl)-2H-  
pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482585-62-6P,  
7-Isobutyl-5-methyl-3-(1-methyl-1H-imidazol-5-yl)-2-[(5-methyl-1H-indol-3-  
y1)methyl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione  
482585-63-7P, 2-(1-Benzothien-3-ylmethyl)-7-isobutyl-5-methyl-3-(1-  
methyl-1H-imidazol-5-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione  
482585-64-8P, 3-(1,3-Dimethyl-2-thioxo-2,3-dihydro-1H-imidazol-4-  
y1)-7-isobutyl-5-methyl-2-[(naphth-1-yl)methyl]-2H-pyrazolo[3,4-  
d]pyrimidine-4,6(5H,7H)-dione 482585-65-9P, 2-[2-[(5-Chloro-1H-  
indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-  
pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-imidazole-4-sulfonamide  
482585-66-0P, 2-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-  
(cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-  
d]pyrimidin-3-yl]-1-methyl-1H-imidazole-4-sulfonamide 482585-67-1P  
, 2-[7-(Cyclopropylmethyl)-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-4,6-  
dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-  
imidazole-4-sulfonamide 482585-68-2P, 2-[2-[(5-Chloro-1-  
(methylsulfonyl)-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-  
4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-imidazole-  
4-sulfonamide 482585-69-3P, 5-[2-[(6-Chloroquinolin-4-yl)methyl]-  
5-methyl-4,6-dioxo-7-propyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-  
3-yl]-1-methyl-1H-pyrrole-3-sulfonamide 482585-77-3P,  
2-[7-Isobutyl-5-methyl-2-[(naphth-1-yl)methyl]-4,6-dioxo-4,5,6,7-  
tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl-1H-imidazole-4-  
sulfonamide 482585-78-4P, 3-[7-Isobutyl-5-methyl-2-[(naphth-1-  
y1)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-  
N-methylbenzenesulfonamide 482585-83-1P, N-(Aminocarbonyl)-3-[7-  
isobutyl-5-methyl-2-[(naphth-1-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-  
pyrazolo[3,4-d]pyrimidin-3-yl]benzenesulfonamide 482585-86-4P,  
7-(Cyclopropylmethyl)-5-methyl-3-(1-methyl-1H-imidazol-5-yl)-2-[(5-methyl-  
1H-indol-3-yl)methyl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione  
trifluoroacetate (1:1) 482585-89-7P, 2-[6-Chloroquinolin-4-  
y1)methyl]-7-(cyclopropylmethyl)-5-methyl-3-(1-methyl-1H-imidazol-5-yl)-2H-  
pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione bis(trifluoroacetate)  
482586-16-3P, 2-[6-Chloroquinolin-4-yl)methyl]-7-isobutyl-5-  
methyl-3-(1-methyl-1H-imidazol-5-yl)-2H-pyrazolo[3,4-d]pyrimidine-  
4,6(5H,7H)-dione 482586-17-4P, 2-[(5-Chloro-1H-indol-3-  
y1)methyl]-7-isobutyl-3-(1-methyl-1H-imidazol-5-yl)-2H-pyrazolo[3,4-  
d]pyrimidine-4,6(5H,7H)-dione 482586-18-5P, 2-[(5-Chloro-1H-  
indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-(1-methyl-1H-imidazol-  
5-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-19-6P  
, 5-[2-[(6-Chloroquinolin-4-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-  
4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-  
sulfonamide 482586-20-9P, 5-[2-[(6-Chloroquinolin-4-yl)methyl]-7-  
(cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-  
d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-sulfonamide 482586-21-0P  
, 2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-3-[1-methyl-4-  
(methylsulfonyl)-1H-imidazol-2-yl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-  
dione 482586-22-1P, 2-[(5-Chloro-1H-indol-3-yl)methyl]-7-  
(cyclopropylmethyl)-5-methyl-3-[1-methyl-4-(methylsulfonyl)-1H-imidazol-2-  
y1]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-23-2P,  
5-[2-[(6-Chloroquinolin-4-yl)methyl]-5-methyl-4,6-dioxo-7-propyl-4,5,6,7-  
tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl-1H-pyrrole-3-  
sulfonamide 482586-24-3P, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-  
7-(cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-


pyrazolo[3, 4-d]pyrimidin-3-yl]-N,1-dimethyl-1H-pyrrole-3-sulfonamide  
 482586-25-4P, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl-1H-pyrrole-3-sulfonamide 482586-26-5P,  
 5-[7-(Cyclopropylmethyl)-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl-1H-pyrrole-3-sulfonamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(antibacterial agent; preparation of pyrazolo[3, 4-d]pyrimidine H. pylori antibacterial agents by cyclocondensation of pyrimidinylhydrazones with aldehydes)


RN 482583-54-0 CAPLUS

CN Acetamide, N-[4-[4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]- (CA INDEX NAME)




RN 482583-56-2 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-7-(2-methylpropyl)-3-(3-methyl-2-thienyl)-2-(1-naphthalenylmethyl)- (CA INDEX NAME)




RN 482583-57-3 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)



RN 482583-59-5 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-7-[(2-methylphenyl)methyl]-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 482583-63-1 CAPLUS

CN Benzoic acid, 3-[7-[(3,5-dimethyl-4-isoxazolyl)methyl]-4,5,6,7-tetrahydro-5-methyl-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)


PAGE 1-A






RN 482583-64-2 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(2-methylpropyl)-5-[2-(4-morpholinyl)ethyl]-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 482583-69-7 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 1-methyl-5-[4,5,6,7-tetrahydro-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-, methyl ester (CA INDEX NAME)




RN 482583-72-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-[2-(dimethylamino)ethyl]-1-methyl- (CA INDEX NAME)




RN 482583-76-6 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-[1-methyl-4-(1H-tetrazol-5-yl)-1H-pyrrol-2-yl]- (9CI) (CA INDEX NAME)




RN 482583-77-7 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-, methyl ester (CA INDEX NAME)




RN 482583-78-8 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-, methyl ester (CA INDEX NAME)




RN 482583-79-9 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 2-[2-(benzo[b]thien-3-ylmethyl)-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-, methyl ester (CA INDEX NAME)




RN 482583-80-2 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 1-methyl-5-[4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-, methyl ester (CA INDEX NAME)




RN 482583-81-3 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[2-[(5-chloro-2-methyl-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-, methyl ester (CA INDEX NAME)




RN 482583-82-4 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[2-[(6-chloro-4-quinolinyl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-, methyl ester (CA INDEX NAME)




RN 482583-83-5 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[2-[(5-fluoro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-, methyl ester (CA INDEX NAME)




RN 482583-84-6 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[2-[(5-cyano-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-, methyl ester (CA INDEX NAME)




RN 482583-85-7 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[7-(cyclopropylmethyl)-2-[(5-ethyl-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-, methyl ester (CA INDEX NAME)




RN 482583-91-5 CAPLUS


CN 1H-Pyrrole-3-carboxylic acid, 5-[2-[(5-chloro-1H-indazol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 482583-92-6 CAPLUS  
CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl- (CA INDEX NAME)



RN 482583-93-7 CAPLUS  
CN 1H-Pyrrole-3-carboxamide, N-cyclopropyl-5-[7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 482583-94-8 CAPLUS  
CN 1H-Pyrrole-3-carboxamide, 5-[7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-methoxy-1-methyl- (CA INDEX NAME)




RN 482583-95-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl- (CA INDEX NAME)




RN 482583-97-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-methoxy-1-methyl- (CA INDEX NAME)




RN 482583-98-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl- (CA INDEX NAME)




RN 482583-99-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-[2-(dimethylamino)ethyl]-1-methyl- (CA INDEX NAME)



RN 482584-00-9 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-cyclopropyl-1-methyl- (CA INDEX NAME)



RN 482584-01-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-methoxy-1-methyl- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 482584-03-2 CAPLUS  
CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)




RN 482584-04-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-(2-aminoethyl)-5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 482584-05-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-N-(1-methylethyl)- (CA INDEX NAME)




RN 482584-06-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-[3-(1H-imidazol-1-yl)propyl]-1-methyl- (CA INDEX NAME)




RN 482584-07-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-(2-hydroxyethyl)-1-methyl- (CA INDEX NAME)




RN 482584-08-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 482584-09-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-N-[2-(methylsulfonyl)ethyl]- (CA INDEX NAME)




RN 482584-10-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-methoxy-1-methyl- (CA INDEX NAME)




RN 482584-11-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-(2-methoxyethyl)-1-methyl- (CA INDEX NAME)




RN 482584-12-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-N-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 482584-13-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-N-[2-[(1-methylethyl)amino]ethyl]- (CA INDEX NAME)




RN 482584-14-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)



RN 482584-15-6 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-cyclopropyl-1-methyl- (CA INDEX NAME)



RN 482584-16-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-[2-(dimethylamino)ethyl]-1-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 482584-17-8 CAPLUS  
CN 1H-Pyrrole-3-carboxamide, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 482584-18-9 CAPLUS


CN 1H-Pyrrole-3-carboxamide, N-cyclopropyl-1-methyl-5-[4,5,6,7-tetrahydro-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




RN 482584-19-0 CAPLUS  
CN 1H-Pyrrole-3-carboxamide, N-methoxy-1-methyl-5-[4,5,6,7-tetrahydro-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)



RN 482584-20-3 CAPLUS  
CN 1H-Pyrrole-3-carboxamide, N,1-dimethyl-5-[4,5,6,7-tetrahydro-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




RN 482584-21-4 CAPLUS  
CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indazol-3-yl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl- (CA INDEX NAME)




RN 482584-22-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indazol-3-yl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-cyclopropyl-1-methyl- (CA INDEX NAME)




RN 482584-23-6 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-N-1H-1,2,4-triazol-3-yl- (9CI) (CA INDEX NAME)



RN 482584-24-7 CAPLUS  
 CN 1H-Pyrrole-3-carboxamide, 5-[2-[(6-chloro-4-quinolinyl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-cyclopropyl-1-methyl- (CA INDEX NAME)




RN 482584-25-8 CAPLUS  
 CN 1H-Pyrrole-3-carboxamide, 5-[2-[(6-chloro-4-quinolinyl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-methoxy-1-methyl- (CA INDEX NAME)




RN 482584-26-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(6-chloro-4-quinolinyl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl- (CA INDEX NAME)




RN 482584-27-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 2-[2-(benzo[b]thien-3-ylmethyl)-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-[2-(dimethylamino)ethyl]-1-methyl- (CA INDEX NAME)




RN 482584-28-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-(benzo[b]thien-3-ylmethyl)-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl- (CA INDEX NAME)




RN 482584-29-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(dimethylamino)ethyl]-1-methyl-5-[4,5,6,7-tetrahydro-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




RN 482584-30-5 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-, 2-(dimethylamino)ethyl ester (CA INDEX NAME)




RN 482584-31-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(6-chloro-4-quinolinyl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-[2-(dimethylamino)ethyl]-1-methyl- (CA INDEX NAME)




RN 482584-32-7 CAPLUS

CN Piperazine, 1-[[5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 482584-33-8 CAPLUS

CN 1*H*-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1*H*-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2*H*-pyrazolo[3,4-d]pyrimidin-3-yl]-N,N,1-trimethyl- (CA INDEX NAME)




RN 482584-34-9 CAPLUS

CN 1*H*-Pyrrole-3-carbonitrile, 5-[2-[(5-chloro-1*H*-indol-3-yl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2*H*-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 482584-35-0 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 482584-36-1 CAPLUS


CN 1H-Pyrrole-3-carbonitrile, 1-methyl-5-[4,5,6,7-tetrahydro-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




RN 482584-37-2 CAPLUS  
CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(4-acetyl-1-methyl-1H-pyrrol-2-yl)-2-[ (5-chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl- (CA INDEX NAME)



RN 482584-38-3 CAPLUS  
CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(4-acetyl-1-methyl-1H-pyrrol-2-yl)-2-[ (6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-5-methyl- (CA INDEX NAME)




RN 482584-41-8 CAPLUS  
CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(2,2-dimethylpropyl)-5-methyl-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 482584-42-9 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(5-chloro-1H-indazol-3-yl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)



RN 482584-43-0 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)- (CA INDEX NAME)



RN 482584-44-1 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-3-(1-methyl-1H-

imidazol-2-yl)-7-(2-methylpropyl)-2-[(5-nitro-1H-indol-3-yl)methyl]- (CA INDEX NAME)




RN 482584-45-2 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-2-methyl-1H-indol-3-yl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482584-46-3 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2-[(5-methyl-1H-indol-3-yl)methyl]-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482584-47-4 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-7-(2-methylpropyl)-3-(1-methyl-1H-pyrrol-2-yl)-2-(1-naphthalenylmethyl)- (CA INDEX NAME)




RN 482584-48-5 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 1-methyl-5-[4,5,6,7-tetrahydro-5-methyl-2-[(2-methyl-1H-indol-3-yl)methyl]-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




RN 482584-49-6 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 482584-50-9 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-ylmethyl)-5-methyl-7-(2-methylpropyl)-3-(3-methyl-2-thienyl)- (CA INDEX NAME)




RN 482584-51-0 CAPLUS

CN 1H-Indole-5-carbonitrile, 3-[[4,5,6,7-tetrahydro-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-2-yl]methyl]- (CA INDEX NAME)




RN 482584-52-1 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-methoxy-1H-indol-3-yl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482584-53-2 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2-[(4-methyl-1H-indol-3-yl)methyl]-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482584-54-3 CAPLUS  
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-3-(2-thienyl)- (CA INDEX NAME)



RN 482584-55-4 CAPLUS  
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-ylmethyl)-5-methyl-7-(2-methylpropyl)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 482584-57-6 CAPLUS  
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[ (5-chloro-1H-indol-3-yl)methyl]-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)-5-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 482584-58-7 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-5-(2-hydroxyethyl)-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482584-59-8 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)-5-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 482584-60-1 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)-5-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 482584-61-2 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-5-methyl-7-(3-methylbutyl)-3-(1-methyl-1H-imidazol-2-yl)- (CA INDEX NAME)





RN 482584-62-3 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-7-(cyclobutylmethyl)-5-methyl-3-(1-methyl-1H-imidazol-2-yl)- (CA INDEX NAME)




RN 482584-64-5 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-7-[(3,5-dimethyl-4-isoxazolyl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-2-yl)- (CA INDEX NAME)



RN 482584-65-6 CAPLUS  
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[ (5-chloro-1H-indol-3-yl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-propyl- (CA INDEX NAME)




RN 482584-66-7 CAPLUS  
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[ (5-chloro-1H-indol-3-yl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-[ (2-methylphenyl)methyl]- (CA INDEX NAME)




RN 482584-67-8 CAPLUS  
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-[ (3,5-dimethyl-4-isoxazolyl)methyl]-5-methyl-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 482584-68-9 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-[(4-hydroxyphenyl)methyl]-5-methyl-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 482584-69-0 CAPLUS

CN Benzoic acid, 3-[(2,4,5,6-tetrahydro-5-methyl-2-(1-naphthalenylmethyl)-4,6-dioxo-3-(4-pyridinyl)-7H-pyrazolo[3,4-d]pyrimidin-7-yl)methyl]- (CA INDEX NAME)




RN 482584-71-4 CAPLUS

CN Benzamide, 3-[(4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl)- (CA INDEX NAME)




RN 482584-72-5 CAPLUS

CN Benzoic acid, 3-[4,5,6,7-tetrahydro-5-methyl-7-(3-methylbutyl)-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




RN 482584-74-7 CAPLUS


CN Benzoic acid, 3-[7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




RN 482584-75-8 CAPLUS  
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(4-amino-1-methyl-1H-imidazol-2-yl)-2-(benzo[b]thien-3-ylmethyl)-5-methyl-7-(2-methylpropyl)-(CA INDEX NAME)



RN 482584-77-0 CAPLUS  
 CN Acetamide, N-[2-[2-(benzo[b]thien-3-ylmethyl)-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-imidazol-4-yl]-(CA INDEX NAME)




RN 482584-79-2 CAPLUS  
 CN Carbamic acid, [2-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-imidazol-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 482584-80-5 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(4-amino-1-methyl-1H-imidazol-2-yl)-2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-5-methyl- (CA INDEX NAME)




RN 482584-81-6 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(2-amino-5-methyl-4-thiazolyl)-2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-5-methyl- (CA INDEX NAME)




RN 482584-83-8 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(2-amino-4-methyl-5-thiazolyl)-2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-5-methyl- (CA INDEX NAME)




RN 482584-85-0 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(2-amino-4-methyl-5-thiazolyl)-2-[(5-chloro-1H-indol-3-yl)methyl]-5-methyl-7-(2-methylpropyl)-  
(CA INDEX NAME)




RN 482584-87-2 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(2-amino-5-methyl-4-thiazolyl)-2-[(5-chloro-1H-indol-3-yl)methyl]-5-methyl-7-(2-methylpropyl)-  
(CA INDEX NAME)




RN 482584-89-4 CAPLUS



CN Carbamic acid, [4-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-5-methyl-2-thiazolyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 482584-90-7 CAPLUS  
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(2-amino-5-methyl-4-thiazolyl)-2-(benzo[b]thien-3-ylmethyl)-5-methyl-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482584-91-8 CAPLUS  
 CN Acetamide, N-[4-[2-(benzo[b]thien-3-ylmethyl)-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-5-methyl-2-thiazolyl]- (CA INDEX NAME)




RN 482584-93-0 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-[1-methyl-4-[2,2,2-trifluoro-1-hydroxyimino)ethyl]-1H-pyrrol-2-yl]- (CA INDEX NAME)




RN 482584-95-2 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-ylmethyl)-5-methyl-7-(2-methylpropyl)-3-(1-methyl-1H-pyrrol-2-yl)- (CA INDEX NAME)




RN 482584-96-3 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)-7-[(trifluoromethyl)sulfinyl]methyl- (CA INDEX NAME)




RN 482584-97-4 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)-7-[(trifluoromethyl)sulfonyl]methyl-  
(CA INDEX NAME)




RN 482584-99-6 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-7-[(methylsulfinyl)methyl]-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)-  
(CA INDEX NAME)




RN 482585-03-5 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-2-(1-naphthalenylmethyl)-7-[ (phenylsulfinyl)methyl]-3-(4-pyridinyl)- (CA INDEX NAME)




RN 482585-05-7 CAPLUS

CN 7H-Pyrazolo[3,4-d]pyrimidine-7-acetonitrile,  $\alpha$ -ethyl-2,4,5,6-tetrahydro-5-methyl-2-(1-naphthalenylmethyl)-4,6-dioxo-3-(4-pyridinyl)- (CA INDEX NAME)




RN 482585-06-8 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-ylmethyl)-3-(2-fluorophenyl)-5-methyl-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482585-07-9 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(3-furanyl)-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)- (CA INDEX NAME)




RN 482585-08-0 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(2,3-dichlorophenyl)methyl]-3-(3-furanyl)-5-methyl-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482585-09-1 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-ylmethyl)-3-(3-furanyl)-5-methyl-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482585-10-4 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(3-bromophenyl)methyl]-5-methyl-7-(2-methylpropyl)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 482585-11-5 CAPLUS

CN Benzonitrile, 3-[4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-3-(4-pyridinyl)-2H-pyrazolo[3,4-d]pyrimidin-2-yl]methyl- (CA INDEX NAME)




RN 482585-12-6 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(3-iodophenyl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482585-13-7 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-2-(1-naphthalenylmethyl)-7-(2-propenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 482585-15-9 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-[2-(dimethylamino)ethyl]-5-methyl-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 482585-16-0 CAPLUS

CN Benzoic acid, 3-[7-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydro-5-methyl-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)



RN 482585-17-1 CAPLUS

CN Benzamide, N-methyl-3-[4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




RN 482585-38-6 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)-7-(2,2,2-trifluoroethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 482585-37-5


CMF C24 H18 F3 N5 O2




CM 2

CRN 76-05-1


CMF C2 H F3 O2




RN 482585-40-0 CAPLUS  
CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2-(1-naphthalenylmethyl)-7-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 482585-41-1 CAPLUS  
CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(3-fluoropropyl)-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2-(1-naphthalenylmethyl)- (CA INDEX NAME)




RN 482585-42-2 CAPLUS  
CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-ylmethyl)-7-(3-fluoropropyl)-5-methyl-3-(1-methyl-1H-imidazol-2-yl)- (CA INDEX NAME)




RN 482585-43-3 CAPLUS  
CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-ylmethyl)-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-propyl- (CA INDEX NAME)




RN 482585-44-4 CAPLUS  
CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-ylmethyl)-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 482585-45-5 CAPLUS  
CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-ylmethyl)-5-methyl-3-(4-pyridinyl)-7-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 482585-46-6 CAPLUS  
CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2-(1-naphthalenylmethyl)-7-propyl- (CA INDEX NAME)




RN 482585-54-6 CAPLUS

CN 1H-Imidazole-4-sulfonamide, 2-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-(1,1-dimethylethyl)-1-methyl- (CA INDEX NAME)




RN 482585-55-7 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-5-yl)-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482585-56-8 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-3-(1-methyl-1H-imidazol-5-yl)-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)- (CA INDEX NAME)




RN 482585-57-9 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-3-(2,3-dihydro-1,3-dimethyl-2-thioxo-1H-imidazol-4-yl)-5-methyl-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482585-58-0 CAPLUS

CN Benzenesulfonamide, 3-[2-[(5-fluoro-3a,7a-dihydrobenzo[b]thien-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




RN 482585-59-1 CAPLUS

CN Benzenesulfonamide, 3-[2-[(3a,7a-dihydro-5-methyl-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




RN 482585-60-4 CAPLUS

CN Benzenesulfonamide, 3-[2-[(5-chloro-3a,7a-dihydro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




RN 482585-61-5 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-fluorobenzo[b]thien-3-yl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-5-yl)-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482585-62-6 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-3-(1-methyl-1H-imidazol-5-yl)-2-[(5-methyl-1H-indol-3-yl)methyl]-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482585-63-7 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-ylmethyl)-5-methyl-3-(1-methyl-1H-imidazol-5-yl)-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482585-64-8 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(2,3-dihydro-1,3-dimethyl-2-thioxo-1H-imidazol-4-yl)-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)- (CA INDEX NAME)




RN 482585-65-9 CAPLUS

CN 1H-Imidazole-4-sulfonamide, 2-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 482585-66-0 CAPLUS

CN 1H-Imidazole-4-sulfonamide, 2-[2-[(5-chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 482585-67-1 CAPLUS

CN 1H-Imidazole-4-sulfonamide, 2-[7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 482585-68-2 CAPLUS

CN 1H-Imidazole-4-sulfonamide, 2-[2-[[5-chloro-1-(methylsulfonyl)-1H-indol-3-yl]methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 482585-69-3 CAPLUS

CN 1H-Pyrrole-3-sulfonamide, 5-[2-[(6-chloro-4-quinolinyl)methyl]-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-7-propyl-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 482585-77-3 CAPLUS

CN 1H-Imidazole-4-sulfonamide, N,1-dimethyl-2-[4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




RN 482585-78-4 CAPLUS

CN Benzenesulfonamide, N-methyl-3-[4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)



RN 482585-83-1 CAPLUS

CN Benzenesulfonamide, N-(aminocarbonyl)-3-[4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




RN 482585-86-4 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(cyclopropylmethyl)-5-methyl-3-(1-methyl-1H-imidazol-5-yl)-2-[(5-methyl-1H-indol-3-yl)methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 482585-85-3

CMF C24 H25 N7 O2



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 482585-89-7 CAPLUS  
CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-(1-methyl-1H-imidazol-5-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 482585-88-6  
CMF C24 H22 Cl N7 O2

PAGE 1-A




PAGE 2-A




CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 482586-16-3 CAPLUS  
CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(6-chloro-4-quinolinyl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-5-yl)-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482586-17-4 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-3-(1-methyl-1H-imidazol-5-yl)-7-(2-methylpropyl)- (CA INDEX NAME)



RN 482586-18-5 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-(1-methyl-1H-imidazol-5-yl)- (CA INDEX NAME)



RN 482586-19-6 CAPLUS

CN 1H-Pyrrole-3-sulfonamide, 5-[2-[(6-chloro-4-quinolinyl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-


d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 482586-20-9 CAPLUS

CN 1H-Pyrrole-3-sulfonamide, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)


PAGE 1-A






RN 482586-21-0 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-5-methyl-3-[1-methyl-4-(methylsulfonyl)-1H-imidazol-2-yl]-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482586-22-1 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-[1-methyl-4-(methylsulfonyl)-1H-imidazol-2-yl]- (CA INDEX NAME)




RN 482586-23-2 CAPLUS

CN 1H-Pyrrole-3-sulfonamide, 5-[2-[(6-chloro-4-quinolinyl)methyl]-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-7-propyl-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl- (CA INDEX NAME)




RN 482586-24-3 CAPLUS

CN 1H-Pyrrole-3-sulfonamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl- (CA INDEX NAME)




RN 482586-25-4 CAPLUS

CN 1H-Pyrrole-3-sulfonamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl- (CA INDEX NAME)



RN 482586-26-5 CAPLUS

CN 1H-Pyrrole-3-sulfonamide, 5-[7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl- (CA INDEX NAME)



IT 482586-27-6P, 5-[7-Isobutyl-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl-1H-pyrrole-3-sulfonamide 482586-28-7P,  
 5-[2-[(6-Chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl-1H-pyrrole-3-sulfonamide 482586-29-8P, 5-[2-[(6-Chloroquinolin-4-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl-1H-pyrrole-3-sulfonamide  
 482586-30-1P, 5-[7-(Cyclopropylmethyl)-2-[(5-fluorobenzothien-3-yl)methyl]-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl-1H-pyrrole-3-sulfonamide  
 482586-31-2P, 5-[2-[(5-Fluorobenzothien-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl-1H-pyrrole-3-sulfonamide 482586-32-3P,  
 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-5-methyl-4,6-dioxo-7-propyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl-1H-pyrrole-3-sulfonamide 482586-33-4P, N-[[5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-

pyrazolo[3, 4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrol-3-yl]sulfonyl]glycine  
482586-34-5P, N-[5-[2-[(6-Chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3, 4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrol-3-yl]sulfonyl]glycine  
482586-35-6P, 2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-3-(1-methyl-1H-imidazol-5-yl)-5-(2-(morpholin-4-yl)ethyl)-2H-pyrazolo[3, 4-d]pyrimidine-4,6(5H, 7H)-dione 482586-36-7P, 2-[(5-Fluorobenzothien-3-yl)methyl]-7-isobutyl-3-(pyridin-4-yl)-2H-pyrazolo[3, 4-d]pyrimidine-4,6(5H, 7H)-dione 482586-37-8P, 2-[(5-Chlorobenzothien-3-yl)methyl]-7-isobutyl-3-(pyridin-4-yl)-2H-pyrazolo[3, 4-d]pyrimidine-4,6(5H, 7H)-dione 482586-38-9P, 2-[(5-Chlorobenzothien-3-yl)methyl]-7-isobutyl-3-(1-methyl-1H-imidazol-2-yl)-2H-pyrazolo[3, 4-d]pyrimidine-4,6(5H, 7H)-dione 482586-39-0P, 2-[(5-Fluorobenzothien-3-yl)methyl]-7-isobutyl-3-(1-methyl-1H-imidazol-2-yl)-2H-pyrazolo[3, 4-d]pyrimidine-4,6(5H, 7H)-dione 482586-40-3P, 2-[(5-Fluorobenzothien-3-yl)methyl]-7-isobutyl-5-methyl-3-(1-methyl-1H-pyrrol-2-yl)-2H-pyrazolo[3, 4-d]pyrimidine-4,6(5H, 7H)-dione 482586-41-4P, 2-[(5-Fluorobenzothien-3-yl)methyl]-7-isobutyl-5-methyl-3-(pyridin-4-yl)-2H-pyrazolo[3, 4-d]pyrimidine-4,6(5H, 7H)-dione 482586-42-5P, N-[5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3, 4-d]pyrimidin-3-yl]pyridin-2-yl]acetamide 482586-43-6P, N-[5-[2-[(5-Fluorobenzothien-3-yl)methyl]-7-isobutyl-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2H-pyrazolo[3, 4-d]pyrimidine-4,6(5H, 7H)-dione 482586-44-7P, 2-[(5-Fluorobenzothien-3-yl)methyl]-7-isobutyl-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2H-pyrazolo[3, 4-d]pyrimidine-4,6(5H, 7H)-dione 482586-45-8P, 2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-3-(4-methyl-4H-1,2,4-triazol-3-yl)-2H-pyrazolo[3, 4-d]pyrimidine-4,6(5H, 7H)-dione 482586-46-9P, 7-Isobutyl-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-3-(4-methyl-4H-1,2,4-triazol-3-yl)-2H-pyrazolo[3, 4-d]pyrimidine-4,6(5H, 7H)-dione 482586-47-0P, 7-(Cyclopropylmethyl)-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-3-(4-methyl-4H-1,2,4-triazol-3-yl)-2H-pyrazolo[3, 4-d]pyrimidine-4,6(5H, 7H)-dione 482586-48-1P, 2-[(5-Chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-(4-methyl-4H-1,2,4-triazol-3-yl)-2H-pyrazolo[3, 4-d]pyrimidine-4,6(5H, 7H)-dione 482586-49-2P, 2-[(5-Chloro-1H-indazol-3-yl)methyl]-7-isobutyl-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2H-pyrazolo[3, 4-d]pyrimidine-4,6(5H, 7H)-dione 482586-50-5P, 2-[(5-Chloro-1H-indazol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2H-pyrazolo[3, 4-d]pyrimidine-4,6(5H, 7H)-dione 482586-51-6P, 2-[(5-Fluorobenzothien-3-yl)methyl]-7-isobutyl-5-methyl-3-(4-methyl-4H-1,2,4-triazol-3-yl)-2H-pyrazolo[3, 4-d]pyrimidine-4,6(5H, 7H)-dione 482586-52-7P, 2-[(5-Chloro-1H-indazol-3-yl)methyl]-7-isobutyl-5-methyl-3-(4-methyl-4H-1,2,4-triazol-3-yl)-2H-pyrazolo[3, 4-d]pyrimidine-4,6(5H, 7H)-dione 482586-53-8P, 2-[(6-Chloroquinolin-4-yl)methyl]-7-isobutyl-5-methyl-3-(4-methyl-4H-1,2,4-triazol-3-yl)-2H-pyrazolo[3, 4-d]pyrimidine-4,6(5H, 7H)-dione 482586-54-9P, 7-(Cyclopropylmethyl)-2-[(5-fluorobenzothien-3-yl)methyl]-5-methyl-3-(4-methyl-4H-1,2,4-triazol-3-yl)-2H-pyrazolo[3, 4-d]pyrimidine-4,6(5H, 7H)-dione 482586-55-0P, 2-[(5-Chloro-1H-indazol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-(4-methyl-4H-1,2,4-triazol-3-yl)-2H-pyrazolo[3, 4-d]pyrimidine-4,6(5H, 7H)-dione 482586-56-1P, [(6-Chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-(4-methyl-4H-1,2,4-triazol-3-yl)-2H-pyrazolo[3, 4-d]pyrimidine-4,6(5H, 7H)-dione 482586-57-2P, 3-(4-Bromo-1-methyl-1H-pyrrol-2-yl)-2-[(5-chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-2H-pyrazolo[3, 4-d]pyrimidine-4,6(5H, 7H)-dione 482586-58-3P, 2-[(5-Chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-[1-methyl-4-(methylsulfinyl)-

1H-pyrrol-2-yl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione  
482586-59-4P, 7-(Cyclopropylmethyl)-2-[ (5-fluorobenzothien-3-  
yl)methyl]-5-methyl-3-[1-methyl-4-(methylsulfinyl)-1H-pyrrol-2-yl]-2H-  
pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-60-7P,  
7-(Cyclopropylmethyl)-5-methyl-2-[ (5-methyl-1H-indol-3-yl)methyl]-3-[1-  
methyl-4-(methylsulfinyl)-1H-pyrrol-2-yl]-2H-pyrazolo[3,4-d]pyrimidine-  
4,6(5H,7H)-dione 482586-61-8P, 2-[ (5-Chloro-1H-indol-3-  
yl)methyl]-7-isobutyl-5-methyl-3-[1-methyl-4-(methylsulfinyl)-1H-pyrrol-2-  
yl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-62-9P,  
7-Isobutyl-5-methyl-2-[ (5-methyl-1H-indol-3-yl)methyl]-3-[1-methyl-4-  
(methylsulfinyl)-1H-pyrrol-2-yl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-  
dione 482586-63-0P, 2-[ (6-Chloroquinolin-4-yl)methyl]-7-isobutyl-  
5-methyl-3-[1-methyl-4-(methylsulfinyl)-1H-pyrrol-2-yl]-2H-pyrazolo[3,4-  
d]pyrimidine-4,6(5H,7H)-dione 482586-64-1P, 2-[ (6-Chloroquinolin-  
4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-[1-methyl-4-(methylsulfinyl)-  
1H-pyrrol-2-yl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione  
482586-65-2P, 7-(Cyclopropylmethyl)-5-methyl-2-[ (5-methyl-1H-indol-  
3-yl)methyl]-3-[1-methyl-4-(methylthio)-1H-pyrrol-2-yl]-2H-pyrazolo[3,4-  
d]pyrimidine-4,6(5H,7H)-dione 482586-66-3P, 2-[ (5-Chloro-1H-  
indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-[1-methyl-4-  
(methylsulfonyl)-1H-pyrrol-2-yl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-  
dione 482586-67-4P, 7-(Cyclopropylmethyl)-5-methyl-2-[ (5-methyl-  
1H-indol-3-yl)methyl]-3-[1-methyl-4-(methylsulfonyl)-1H-pyrrol-2-yl]-2H-  
pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-68-5P,  
7-(Cyclopropylmethyl)-2-[ (5-fluorobenzothien-3-yl)methyl]-5-methyl-3-[1-  
methyl-4-(methylsulfonyl)-1H-pyrrol-2-yl]-2H-pyrazolo[3,4-d]pyrimidine-  
4,6(5H,7H)-dione 482586-69-6P, 2-[ (6-Chloroquinolin-4-yl)methyl]-  
7-(cyclopropylmethyl)-5-methyl-3-[1-methyl-4-(methylsulfonyl)-1H-pyrrol-2-  
yl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-71-0P,  
3-[ (4-Acetyl-1-methyl-1H-pyrrol-2-yl)-2-[ (5-chloro-1H-indol-3-yl)methyl]-7-  
isobutyl-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione  
482586-72-1P, 1-[5-[2-[ (5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-  
5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-  
methyl-1H-pyrrol-3-yl]ethylidenecyanamide 482586-73-2P,  
2-[ (5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-3-[1-methyl-4-  
propionyl-1H-pyrrol-2-yl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione  
482586-74-3P, 2-[ (5-Chloro-1H-indol-3-yl)methyl]-3-[4-((1E)-N-  
hydroxyethanimidoyl)-1-methyl-1H-pyrrol-2-yl]-7-isobutyl-5-methyl-2H-  
pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-75-4P,  
2-[ (5-Chloro-1H-indol-3-yl)methyl]-3-[4-(1-hydroxyethyl)-1-methyl-1H-  
pyrrol-2-yl]-7-isobutyl-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-  
dione 482586-76-5P, 2-[ (5-Chloro-1H-indol-3-yl)methyl]-7-  
isobutyl-3-[4-((1E)-N-methoxyethanimidoyl)-1-methyl-1H-pyrrol-2-yl]-5-  
methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-77-6P  
, 2-[ (5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-3-[4-isobutyryl-1-methyl-  
1H-imidazol-2-yl]-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione  
482586-79-8P, 3-[ (4-Acetyl-1-methyl-1H-imidazol-2-yl)-2-[ (5-chloro-  
1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-  
4,6(5H,7H)-dione 482586-81-2P, 3-[ (4-Acetyl-1-methyl-1H-pyrrol-2-  
yl)-2-[ (6-chloroquinolin-4-yl)methyl]-7-isobutyl-5-methyl-2H-pyrazolo[3,4-  
d]pyrimidine-4,6(5H,7H)-dione 482586-82-3P, 2-(Benzothien-3-  
ylmethyl)-5-(2-hydroxyethyl)-7-isobutyl-3-(1-methyl-1H-pyrrol-2-yl)-2H-  
pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-83-4P,  
2-[ (6-Chloroquinolin-4-yl)methyl]-7-isobutyl-5-methyl-3-[1-methyl-1H-  
pyrrol-2-yl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione  
482586-84-5P, 2-(Benzothien-3-ylmethyl)-7-isobutyl-3-(1-methyl-1H-  
pyrrol-2-yl)-5-(pyridin-2-ylmethyl)-2H-pyrazolo[3,4-d]pyrimidine-  
4,6(5H,7H)-dione 482586-85-6P, 2-[ (6-Fluoroquinolin-4-yl)methyl]-  
7-isobutyl-5-methyl-3-(1-methyl-4-propionyl-1H-pyrrol-2-yl)-2H-


pyrazolo[3, 4-d]pyrimidine-4, 6(5H, 7H)-dione 482586-87-8P,  
2-(Benzothien-3-ylmethyl)-7-isobutyl-3-(1-methyl-1H-pyrrol-2-yl)-5-(2-(morpholin-4-yl)ethyl)-2H-pyrazolo[3, 4-d]pyrimidine-4, 6(5H, 7H)-dione  
482586-88-9P, 3-(4-Acetyl-1-methyl-1H-pyrrol-2-yl)-2-[ (6-fluoroquinolin-4-yl)methyl]-7-isobutyl-5-methyl-2H-pyrazolo[3, 4-d]pyrimidine-4, 6(5H, 7H)-dione 482586-89-0P, 2-(Benzothien-3-ylmethyl)-7-isobutyl-3-(1-methyl-1H-pyrrol-2-yl)-5-(pyridin-3-ylmethyl)-2H-pyrazolo[3, 4-d]pyrimidine-4, 6(5H, 7H)-dione 482586-90-3P,  
2-(Benzothien-3-ylmethyl)-5-[2-[ (2S)-2-[(dimethylamino)methyl]morpholin-4-yl]ethyl]-7-isobutyl-3-(1-methyl-1H-pyrrol-2-yl)-2H-pyrazolo[3, 4-d]pyrimidine-4, 6(5H, 7H)-dione 482586-91-4P, 2-(Benzothien-3-ylmethyl)-7-isobutyl-3-(1-methyl-1H-pyrrol-2-yl)-5-(2-(piperidin-1-yl)ethyl)-2H-pyrazolo[3, 4-d]pyrimidine-4, 6(5H, 7H)-dione  
482586-92-5P, 2-(Benzothien-3-ylmethyl)-5-[2-(dimethylamino)ethyl]-7-isobutyl-3-(1-methyl-1H-pyrrol-2-yl)-2H-pyrazolo[3, 4-d]pyrimidine-4, 6(5H, 7H)-dione 482586-93-6P, 2-(Benzothien-3-ylmethyl)-7-isobutyl-5-[(1-methylpiperidin-3-yl)methyl]-3-(1-methyl-1H-pyrrol-2-yl)-2H-pyrazolo[3, 4-d]pyrimidine-4, 6(5H, 7H)-dione 482586-94-7P,  
2-[ (5-Chloro-1H-indol-3-yl)methyl]-3-[4-[(dimethylamino)acetyl]-1-methyl-1H-pyrrol-2-yl]-7-isobutyl-5-methyl-2H-pyrazolo[3, 4-d]pyrimidine-4, 6(5H, 7H)-dione 482586-95-8P, 2-(Benzothien-3-ylmethyl)-7-isobutyl-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2H-pyrazolo[3, 4-d]pyrimidine-4, 6(5H, 7H)-dione 482586-96-9P, 2-[ (6-Chloroquinolin-4-yl)methyl]-7-isobutyl-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2H-pyrazolo[3, 4-d]pyrimidine-4, 6(5H, 7H)-dione 482586-97-0P,  
2-[ (6-Fluoroquinolin-4-yl)methyl]-7-isobutyl-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2H-pyrazolo[3, 4-d]pyrimidine-4, 6(5H, 7H)-dione  
482586-98-1P, 2-(Benzothien-3-ylmethyl)-5-[2-(1H-imidazol-1-yl)ethyl]-7-isobutyl-3-(1-methyl-1H-pyrrol-2-yl)-2H-pyrazolo[3, 4-d]pyrimidine-4, 6(5H, 7H)-dione 482587-00-8P, 2-[ (5-Chloro-1H-indol-3-yl)methyl]-3-(1-ethyl-1H-pyrrol-2-yl)-7-isobutyl-5-methyl-2H-pyrazolo[3, 4-d]pyrimidine-4, 6(5H, 7H)-dione 482587-01-9P,  
N-[2-[2-(1-Benzothien-3-ylmethyl)-7-isobutyl-3-(1-methyl-1H-pyrrol-2-yl)-4, 6-dioxo-2, 4, 6, 7-tetrahydro-5H-pyrazolo[3, 4-d]pyrimidin-5-yl]ethyl]guanidine 482587-02-0P, 3-(4-Acetyl-1-methyl-1H-pyrrol-2-yl)-7-isobutyl-5-methyl-2-[ [6-(trifluoromethyl)quinolin-4-yl]methyl]-2H-pyrazolo[3, 4-d]pyrimidine-4, 6(5H, 7H)-dione 482587-04-2P,  
2-(Benzothien-3-ylmethyl)-7-isobutyl-3-(1-methyl-1H-pyrrol-2-yl)-5-[2-(1H-pyrazol-1-yl)ethyl]-2H-pyrazolo[3, 4-d]pyrimidine-4, 6(5H, 7H)-dione  
482587-05-3P, 7-Isobutyl-5-methyl-3-(1-methyl-4-propionyl-1H-pyrrol-2-yl)-2-[ [6-(trifluoromethyl)quinolin-4-yl]methyl]-2H-pyrazolo[3, 4-d]pyrimidine-4, 6(5H, 7H)-dione 482587-06-4P, 7-(Cyclopropylmethyl)-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2-[ [5-(trifluoromethyl)-1H-indol-3-yl]methyl]-2H-pyrazolo[3, 4-d]pyrimidine-4, 6(5H, 7H)-dione 482587-07-5P, 7-(Cyclopropylmethyl)-5-methyl-3-(1-methyl-1H-pyrrol-2-yl)-2-[ [5-(trifluoromethyl)-1H-indol-3-yl]methyl]-2H-pyrazolo[3, 4-d]pyrimidine-4, 6(5H, 7H)-dione 482587-09-7P,  
2-[ (6-Chloroquinolin-4-yl)methyl]-7-isobutyl-3-(4-methyl-4H-1, 2, 4-triazol-3-yl)-5-(2-(morpholin-4-yl)ethyl)-2H-pyrazolo[3, 4-d]pyrimidine-4, 6(5H, 7H)-dione 482587-10-0P, [2-[ (6-Chloroquinolin-4-yl)methyl]-7-isobutyl-3-(4-methyl-4H-1, 2, 4-triazol-3-yl)-4, 6-dioxo-2, 4, 6, 7-tetrahydro-5H-pyrazolo[3, 4-d]pyrimidin-5-yl]acetonitrile 482587-14-4P,  
7-(Cyclopropylmethyl)-3-((3R)-3-hydroxypyrrolidin-1-yl)-5-methyl-2-[(naphth-1-yl)methyl]-2H-pyrazolo[3, 4-d]pyrimidine-4, 6(5H, 7H)-dione  
482587-15-5P, 2-[ (5-Chlorobenzothien-3-yl)methyl]-7-isobutyl-5-methyl-3-(piperazin-1-yl)-2H-pyrazolo[3, 4-d]pyrimidine-4, 6(5H, 7H)-dione  
482587-16-6P, 7-Isobutyl-5-methyl-2-[(naphth-1-yl)methyl]-3-(piperazin-1-yl)-2H-pyrazolo[3, 4-d]pyrimidine-4, 6(5H, 7H)-dione  
482587-17-7P, 2-[ (5-Chlorobenzothien-3-yl)methyl]-7-isobutyl-5-

methyl-3-(4-methylpiperazin-1-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482587-19-9P, 2-[(5-Chlorobenzothien-3-yl)methyl]-7-isobutyl-5-methyl-3-(piperidin-1-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482587-20-2P, 2-[(5-Chlorobenzothien-3-yl)methyl]-7-isobutyl-5-methyl-3-(morpholin-4-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482587-21-3P, 2-[(6-Chloroquinolin-4-yl)methyl]-3-(3-hydroxypyrrolidin-1-yl)-7-isobutyl-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482587-22-4P, 2-[(6-Chloroquinolin-4-yl)methyl]-7-isobutyl-5-methyl-3-(piperazin-1-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482587-23-5P, 7-(Cyclopropylmethyl)-5-methyl-2-(naphth-1-ylmethyl)-3-(piperazin-1-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482587-24-6P, 4-[7-(Cyclopropylmethyl)-5-methyl-2-(naphth-1-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,N-dimethylpiperazine-1-sulfonamide 482587-25-7P, 7-(Cyclopropylmethyl)-3-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methyl-2-[(naphth-1-yl)methyl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482587-26-8P, 7-(Cyclopropylmethyl)-3-(3-hydroxypiperidin-1-yl)-5-methyl-2-[(naphth-1-yl)methyl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482587-27-9P, 3-[(3S)-3-Aminopyrrolidin-1-yl]-7-(cyclopropylmethyl)-5-methyl-2-[(naphth-1-yl)methyl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482587-28-0P, 3-[(3R)-3-Aminopyrrolidin-1-yl]-7-(cyclopropylmethyl)-5-methyl-2-[(naphth-1-yl)methyl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482587-29-1P, 2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-3-(3-Methylisoxazol-4-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482587-30-4P, 5-[2-[(6-Chloroquinolin-4-yl)methyl]-7-isobutyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carbonitrile 482587-31-5P, 2-[(6-Chloroquinolin-4-yl)methyl]-7-isobutyl-3-(1-methyl-1H-pyrrol-2-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(antibacterial agent; preparation of pyrazolo[3,4-d]pyrimidine H. pylori antibacterial agents by cyclocondensation of pyrimidinylhydrazones with aldehydes)

RN 482586-27-6 CAPLUS


CN 1H-Pyrrole-3-sulfonamide, N,1-dimethyl-5-[4,5,6,7-tetrahydro-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




RN 482586-28-7 CAPLUS

CN 1H-Pyrrole-3-sulfonamide, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 482586-29-8 CAPLUS

CN 1H-Pyrrole-3-sulfonamide, 5-[2-[(6-chloro-4-quinolinyl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl- (CA INDEX NAME)




RN 482586-30-1 CAPLUS

CN 1H-Pyrrole-3-sulfonamide, 5-[7-(cyclopropylmethyl)-2-[ (5-fluorobenzo[b]thien-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl- (CA INDEX NAME)




RN 482586-31-2 CAPLUS

CN 1H-Pyrrole-3-sulfonamide, 5-[2-[ (5-fluorobenzo[b]thien-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl- (CA INDEX NAME)




RN 482586-32-3 CAPLUS

CN 1H-Pyrrole-3-sulfonamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-7-propyl-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl- (CA INDEX NAME)



RN 482586-33-4 CAPLUS


CN Glycine, N-[5-[2-[(5-chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrol-3-ylsulfonyl]- (CA INDEX NAME)




RN 482586-34-5 CAPLUS

CN Glycine, N-[5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrol-3-ylsulfonyl]- (CA INDEX NAME)


PAGE 1-A






RN 482586-35-6 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-3-(1-methyl-1H-imidazol-5-yl)-7-(2-methylpropyl)-5-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 482586-36-7 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-fluorobenzo[b]thien-3-yl)methyl]-7-(2-methylpropyl)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 482586-37-8 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chlorobenzo[b]thien-3-yl)methyl]-7-(2-methylpropyl)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 482586-38-9 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chlorobenzo[b]thien-3-yl)methyl]-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482586-39-0 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-fluorobenzo[b]thien-3-yl)methyl]-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482586-40-3 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-fluorobenzo[b]thien-3-yl)methyl]-5-methyl-7-(2-methylpropyl)-3-(1-methyl-1H-pyrrol-2-yl)- (CA INDEX NAME)




RN 482586-41-4 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[ (5-fluorobenzo[b]thien-3-yl)methyl]-5-methyl-7-(2-methylpropyl)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 482586-42-5 CAPLUS

CN Acetamide, N-[5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-pyridinyl]- (CA INDEX NAME)




RN 482586-43-6 CAPLUS

CN Acetamide, N-[5-[2-[(5-fluorobenzo[b]thien-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-pyridinyl]- (CA INDEX NAME)




RN 482586-44-7 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-fluorobenzo[b]thien-3-yl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482586-45-8 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-5-methyl-7-(2-methylpropyl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)- (CA INDEX NAME)




RN 482586-46-9 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-7-(2-methylpropyl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)- (CA INDEX NAME)




RN 482586-47-0 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(cyclopropylmethyl)-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-3-(4-methyl-4H-1,2,4-triazol-3-yl)- (CA INDEX NAME)




RN 482586-48-1 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-(4-methyl-4H-1,2,4-triazol-3-yl)- (CA INDEX NAME)




RN 482586-49-2 CAPLUS  
CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indazol-3-yl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)-(CA INDEX NAME)



RN 482586-50-5 CAPLUS  
CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indazol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-(CA INDEX NAME)




RN 482586-51-6 CAPLUS  
CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-fluorobenzo[b]thien-3-yl)methyl]-5-methyl-7-(2-methylpropyl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)-(CA INDEX NAME)




RN 482586-52-7 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indazol-3-yl)methyl]-5-methyl-7-(2-methylpropyl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)-(CA INDEX NAME)




RN 482586-53-8 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(6-chloro-4-quinolinyl)methyl]-5-methyl-7-(2-methylpropyl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)-(CA INDEX NAME)




RN 482586-54-9 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(cyclopropylmethyl)-2-[(5-fluorobenzo[b]thien-3-yl)methyl]-5-methyl-3-(4-methyl-4H-1,2,4-triazol-3-yl)-(CA INDEX NAME)




RN 482586-55-0 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[ (5-chloro-1H-indazol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-(4-methyl-4H-1,2,4-triazol-3-yl)- (CA INDEX NAME)




RN 482586-56-1 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[ (6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-(4-methyl-4H-1,2,4-triazol-3-yl)- (CA INDEX NAME)




RN 482586-57-2 CAPLUS

RN 462360-37-2 CASLCS  
CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(4-bromo-1-methyl-1H-pyrrol-2-yl)-2-[(5-chloro-1H-indol-3-yl)methyl]-5-methyl-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482586-58-3 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[ (5-chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-[1-methyl-4-(methylsulfinyl)-1H-pyrrol-2-yl]- (CA INDEX NAME)




RN 482586-59-4 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(cyclopropylmethyl)-2-[(5-fluorobenzo[b]thien-3-yl)methyl]-5-methyl-3-[1-methyl-4-(methylsulfinyl)-1H-pyrrol-2-yl]- (CA INDEX NAME)




RN 482586-60-7 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(cyclopropylmethyl)-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-3-[1-methyl-4-(methylsulfinyl)-1H-pyrrol-2-yl]- (CA INDEX NAME)




RN 482586-61-8 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-5-methyl-3-[1-methyl-4-(methylsulfinyl)-1H-pyrrol-2-yl]-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482586-62-9 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-3-[1-methyl-4-(methylsulfinyl)-1H-pyrrol-2-yl]-7-(2-methylpropyl)- (CA INDEX NAME)



RN 482586-63-0 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(6-chloro-4-quinolinyl)methyl]-5-methyl-3-[1-methyl-4-(methylsulfinyl)-1H-pyrrol-2-yl]-7-(2-methylpropyl)- (CA INDEX NAME)



RN 482586-64-1 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-[1-methyl-4-(methylsulfinyl)-1H-pyrrol-2-yl]- (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 482586-65-2 CAPLUS  
CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(cyclopropylmethyl)-5-methyl-2-[ (5-methyl-1H-indol-3-yl)methyl]-3-[1-methyl-4-(methylthio)-1H-pyrrol-2-yl]- (CA INDEX NAME)




RN 482586-66-3 CAPLUS  
CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-[1-methyl-4-(methylsulfonyl)-1H-pyrrol-2-yl]- (CA INDEX NAME)



RN 482586-67-4 CAPLUS  
CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(cyclopropylmethyl)-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-3-[1-methyl-4-(methylsulfonyl)-1H-pyrrol-2-yl]- (CA INDEX NAME)




RN 482586-68-5 CAPLUS  
CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(cyclopropylmethyl)-2-[(5-fluorobenzo[b]thien-3-yl)methyl]-5-methyl-3-[1-methyl-4-(methylsulfonyl)-1H-pyrrol-2-yl]- (CA INDEX NAME)




RN 482586-69-6 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-[1-methyl-4-(methylsulfonyl)-1H-pyrrol-2-yl]- (CA INDEX NAME)


PAGE 1-A






RN 482586-71-0 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(4-acetyl-1-methyl-1H-pyrrol-2-yl)-2-[5-chloro-1H-indol-3-yl)methyl]-5-methyl-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482586-72-1 CAPLUS

CN Cyanamide, [1-[5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrol-3-yl]ethylidene]- (9CI) (CA INDEX NAME)



RN 482586-73-2 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-5-methyl-3-[1-methyl-4-(1-oxopropyl)-1H-pyrrol-2-yl]-7-(2-methylpropyl)- (CA INDEX NAME)



RN 482586-74-3 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-3-[4-[(1E)-1-(hydroxyimino)ethyl]-1-methyl-1H-pyrrol-2-yl]-5-methyl-7-(2-methylpropyl)- (CA INDEX NAME)

Double bond geometry as shown.




RN 482586-75-4 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-3-[4-(1-hydroxyethyl)-1-methyl-1H-pyrrol-2-yl]-5-methyl-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482586-76-5 CAPLUS  
CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-3-[4-[(1E)-1-(methoxyimino)ethyl]-1-methyl-1H-pyrrol-2-yl]-5-methyl-7-(2-methylpropyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 482586-77-6 CAPLUS  
CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-5-methyl-3-[1-methyl-4-(2-methyl-1-oxopropyl)-1H-imidazol-2-yl]-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482586-79-8 CAPLUS  
CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(4-acetyl-1-methyl-1H-imidazol-2-yl)-2-[(5-chloro-1H-indol-3-yl)methyl]-5-methyl-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482586-81-2 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(4-acetyl-1-methyl-1H-pyrrol-2-yl)-2-[6-chloro-4-(1H-pyrazol-1-yl)methyl]-5-methyl-7-(2-methylpropyl)-  
(CA INDEX NAME)




RN 482586-82-3 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-ylmethyl)-5-(2-hydroxyethyl)-7-(2-methylpropyl)-3-(1-methyl-1H-pyrrol-2-yl)-  
(CA INDEX NAME)




RN 482586-83-4 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[6-chloro-4-(1H-pyrazol-1-yl)methyl]-5-methyl-7-(2-methylpropyl)-3-(1-methyl-1H-pyrrol-2-yl)-  
(CA INDEX NAME)




RN 482586-84-5 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-ylmethyl)-7-(2-methylpropyl)-3-(1-methyl-1H-pyrrol-2-yl)-5-(2-pyridinylmethyl)- (CA INDEX NAME)



RN 482586-85-6 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(6-fluoro-4-quinolinyl)methyl]-5-methyl-3-[1-methyl-4-(1-oxopropyl)-1H-pyrrol-2-yl]-7-(2-methylpropyl)- (CA INDEX NAME)



RN 482586-87-8 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-

ylmethyl)-7-(2-methylpropyl)-3-(1-methyl-1H-pyrrol-2-yl)-5-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 482586-88-9 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(4-acetyl-1-methyl-1H-pyrrol-2-yl)-2-[(6-fluoro-4-quinolinyl)methyl]-5-methyl-7-(2-methylpropyl)- (CA INDEX NAME)



RN 482586-89-0 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-ylmethyl)-7-(2-methylpropyl)-3-(1-methyl-1H-pyrrol-2-yl)-5-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 482586-90-3 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-


ylmethyl)-5-[2-[(2S)-2-[(dimethylamino)methyl]-4-morpholinyl]ethyl]-7-(2-methylpropyl)-3-(1-methyl-1H-pyrrol-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 482586-91-4 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-ylmethyl)-7-(2-methylpropyl)-3-(1-methyl-1H-pyrrol-2-yl)-5-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)




RN 482586-92-5 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-ylmethyl)-5-[2-(dimethylamino)ethyl]-7-(2-methylpropyl)-3-(1-methyl-1H-pyrrol-2-yl)- (CA INDEX NAME)




RN 482586-93-6 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-ylmethyl)-5-[(1-methyl-3-piperidinyl)methyl]-7-(2-methylpropyl)-3-(1-methyl-1H-pyrrol-2-yl)- (CA INDEX NAME)




RN 482586-94-7 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[5-chloro-1H-indol-3-ylmethyl]-3-[4-(dimethylamino)acetyl]-1-methyl-1H-pyrrol-2-yl]-5-methyl-7-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 482586-95-8 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-ylmethyl)-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482586-96-9 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[6-chloro-4-quinolinylmethyl]-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482586-97-0 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(6-fluoro-4-quinolinyl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482586-98-1 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-ylmethyl)-5-[2-(1H-imidazol-1-yl)ethyl]-7-(2-methylpropyl)-3-(1-methyl-1H-pyrrol-2-yl)- (CA INDEX NAME)




RN 482587-00-8 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-3-(1-ethyl-1H-pyrrol-2-yl)-5-methyl-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482587-01-9 CAPLUS

CN Guanidine, [2-[2-(benzo[b]thien-3-ylmethyl)-2,4,6,7-tetrahydro-7-(2-methylpropyl)-3-(1-methyl-1H-pyrrol-2-yl)-4,6-dioxo-5H-pyrazolo[3,4-d]pyrimidin-5-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 482587-02-0 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(4-acetyl-1-methyl-1H-pyrrol-2-yl)-5-methyl-7-(2-methylpropyl)-2-[[6-(trifluoromethyl)-4-quinolinyl]methyl]- (CA INDEX NAME)




RN 482587-04-2 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-ylmethyl)-7-(2-methylpropyl)-3-(1-methyl-1H-pyrrol-2-yl)-5-[2-(1H-pyrazol-1-yl)ethyl]- (CA INDEX NAME)




RN 482587-05-3 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-3-[1-methyl-4-(1-oxopropyl)-1H-pyrrol-2-yl]-7-(2-methylpropyl)-2-[[6-(trifluoromethyl)-4-quinolinyl]methyl]- (CA INDEX NAME)



RN 482587-06-4 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(cyclopropylmethyl)-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2-[[5-(trifluoromethyl)-1H-indol-3-yl]methyl]- (CA INDEX NAME)



RN 482587-07-5 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(cyclopropylmethyl)-5-

methyl-3-(1-methyl-1H-pyrrol-2-yl)-2-[5-(trifluoromethyl)-1H-indol-3-yl]methyl]- (CA INDEX NAME)




RN 482587-09-7 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[6-chloro-4-quinolinyl)methyl]-7-(2-methylpropyl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)-5-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 482587-10-0 CAPLUS


CN 5H-Pyrazolo[3,4-d]pyrimidine-5-acetonitrile, 2-[6-chloro-4-quinolinyl)methyl]-2,4,6,7-tetrahydro-7-(2-methylpropyl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)-4,6-dioxo- (CA INDEX NAME)



RN 482587-14-4 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(cyclopropylmethyl)-3-[(3R)-3-hydroxy-1-pyrrolidinyl]-5-methyl-2-(1-naphthalenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 482587-15-5 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chlorobenzo[b]thien-3-yl)methyl]-5-methyl-7-(2-methylpropyl)-3-(1-piperazinyl)- (CA INDEX NAME)




RN 482587-16-6 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-3-(1-piperazinyl)- (CA INDEX NAME)




RN 482587-17-7 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chlorobenzo[b]thien-3-yl)methyl]-5-methyl-3-(4-methyl-1-piperazinyl)-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482587-19-9 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chlorobenzo[b]thien-3-yl)methyl]-5-methyl-7-(2-methylpropyl)-3-(1-piperidinyl)- (CA INDEX NAME)




RN 482587-20-2 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chlorobenzo[b]thien-3-yl)methyl]-5-methyl-7-(2-methylpropyl)-3-(4-morpholinyl)- (CA INDEX NAME)




RN 482587-21-3 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(6-chloro-4-quinolinyl)methyl]-3-(3-hydroxy-1-pyrrolidinyl)-5-methyl-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482587-22-4 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(6-chloro-4-quinolinyl)methyl]-5-methyl-7-(2-methylpropyl)-3-(1-piperazinyl)- (CA INDEX NAME)




RN 482587-23-5 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(cyclopropylmethyl)-5-methyl-2-(1-naphthalenylmethyl)-3-(1-piperazinyl)- (CA INDEX NAME)



RN 482587-24-6 CAPLUS


CN 1-Piperazinesulfonamide, 4-[7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,N-dimethyl- (CA INDEX NAME)



RN 482587-25-7 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(cyclopropylmethyl)-3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-5-methyl-2-(1-naphthalenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 482587-26-8 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(cyclopropylmethyl)-3-(3-hydroxy-1-piperidinyl)-5-methyl-2-(1-naphthalenylmethyl)- (CA INDEX NAME)



RN 482587-27-9 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-[(3S)-3-amino-1-pyrrolidinyl]-7-(cyclopropylmethyl)-5-methyl-2-(1-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 482587-28-0 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-[(3R)-3-amino-1-pyrrolidinyl]-7-(cyclopropylmethyl)-5-methyl-2-(1-naphthalenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 482587-29-1 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-5-methyl-3-(3-methyl-4-isoxazolyl)-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482587-30-4 CAPLUS

CN 1*H*-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-4,5,6,7-tetrahydro-7-(2-methylpropyl)-4,6-dioxo-2*H*-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)



RN 482587-31-5 CAPLUS

CN 2*H*-Pyrazolo[3,4-d]pyrimidine-4,6(5*H*,7*H*)-dione, 2-[(6-chloro-4-quinolinyl)methyl]-7-(2-methylpropyl)-3-(1-methyl-1*H*-pyrrol-2-yl)- (CA INDEX NAME)




IT 482583-62-0P, 5-Methyl-2-[(naphth-1-yl)methyl]-3-(pyridin-4-yl)-2*H*-pyrazolo[3,4-d]pyrimidine-4,6(5*H*,7*H*)-dione 482583-68-6P,  
7-Isobutyl-2-[(naphth-1-yl)methyl]-3-(pyridin-4-yl)-2*H*-pyrazolo[3,4-d]pyrimidine-4,6(5*H*,7*H*)-dione 482585-04-6P, 3-[7-Isobutyl-5-

methyl-2-[ (naphth-1-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]benzonitrile  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of pyrazolo[3,4-d]pyrimidine H. pylori  
antibacterial agents by cyclocondensation of pyrimidinylhydrazones with  
aldehydes)


RN 482583-62-0 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 482583-68-6 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)- (CA INDEX NAME)



RN 482585-04-6 CAPLUS

CN Benzonitrile, 3-[4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




IT 482583-96-0, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carboxylic acid  
 482584-02-1, 5-[2-[(6-Chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carboxylic acid  
 482584-63-4, 2-[(5-Chloro-1H-indol-3-yl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione  
 482584-73-6D, 3-[5-Methyl-2-[(naphth-1-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]benzoic acid, resin bound 482584-78-1, 3-(4-Amino-1-methyl-1H-imidazol-2-yl)-2-(benzothien-3-ylmethyl)-7-isobutyl-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione hydrochloride 482584-92-9, 3-(2-Amino-5-methyl-1,3-thiazol-4-yl)-2-(benzothien-3-ylmethyl)-7-isobutyl-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione hydrochloride

RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of pyrazolo[3,4-d]pyrimidine H. pylori antibacterial agents by cyclocondensation of pyrimidinylhydrazones with aldehydes)

RN 482583-96-0 CAPPLUS


CN 1H-Pyrrole-3-carboxylic acid, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)



RN 482584-02-1 CAPPLUS


CN 1H-Pyrrole-3-carboxylic acid, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-

(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 482584-63-4 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 482584-73-6 CAPLUS

CN Benzoic acid, 3-[2,4,5,6-tetrahydro-5-methyl-2-(1-naphthalenylmethyl)-4,6-dioxo-1H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)



RN 482584-78-1 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(4-amino-1-methyl-1H-imidazol-2-yl)-2-(benzo[b]thien-3-ylmethyl)-5-methyl-7-(2-methylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 482584-92-9 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(2-amino-5-methyl-4-thiazolyl)-2-(benzo[b]thien-3-ylmethyl)-5-methyl-7-(2-methylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


GI





AB Title compds. I [wherein R1 and R2 = independently H, NH<sub>2</sub>, or (un)substituted (cyclo)alkyl, (cyclo)alkenyl, alkynyl, aryl, alkoxy, or heterocyclyl; R3 = (un)substituted monocyclic or bicyclic ring system comprising 0-3 heteroatoms independently selected from N, O, or S; R4 = (un)substituted alkyl or (di)alkylamino, with exceptions; Y = CH<sub>2</sub>, CHCH<sub>3</sub>, SO, or SO<sub>2</sub>; and pharmaceutically acceptable salts thereof] were prepared. For example, 6-hydrazino-1-isobutyl-3-methylpyrimidine-2,4-(1H,3H)-dione (4-step preparation given) was condensed with 1-naphthaldehyde in MeOH to give the hydrazone. Cyclocondensation with N-(4-formylphenyl)acetamide in DMF afforded II. Compds. of the invention exhibited glutamate racemase (MurI) activity with IC<sub>50</sub> values of < 400 μM. Thus, I and pharmaceutical compns. containing them are useful in the treatment or prophylaxis of *Helicobacter pylori* (*H. pylori*) infection (no data).

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1983:53834 CAPLUS  
 DOCUMENT NUMBER: 98:53834  
 ORIGINAL REFERENCE NO.: 98:8285a,8288a  
 TITLE: Construction of pyrimido[5,4-e]-as-triazine, purine,  
       v-triazolo[4,5-d]pyrimidine and pyrazolo[3,4-  
       d]pyrimidine ring systems from 5-arylazo-6-  
       arylidenehydrazino-1,3-dimethyluracils.  
 AUTHOR(S): Nishigaki, Sadao; Ichiba, Misuzu; Fukami, Kiyoko;  
              Senga, Keitaro  
 CORPORATE SOURCE: Sch. Med., Keio Univ., Tokyo, 160, Japan  
 SOURCE: Journal of Heterocyclic Chemistry (1982), 19(4),  
         769-73  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 54014-88-9P  
     RL: SPN (Synthetic preparation); PREP (Preparation)  
           (preparation of)  
 RN 54014-88-9 CAPLUS  
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5,7-dimethyl-3-phenyl-2-  
       (phenylmethyl)- (CA INDEX NAME)




GI




AB Reaction of (arylazo)hydrazinouracils I ( $R = H, NO_2$ ;  $R1 = H, Br, Cl, MeO, Me_2N$ ), prepared by treatment of hydrazinouracils with diazotized arylamines,

with Me<sub>2</sub>NCH(OMe)<sub>2</sub> gave pyrimidotriazines II, while thermolysis of I gave purines,  $\nu$ -triazolo[4,5-d]pyrimidines, and pyrazolo[3,4-d]pyrimidines instead of the expected II. Mechanisms were proposed for the formation of the various ring systems in these reactions.


L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1977:468272 CAPLUS  
 DOCUMENT NUMBER: 87:68272  
 ORIGINAL REFERENCE NO.: 87:10873a,10876a  
 TITLE: Synthesis of pyrazolo[3,4-d]pyrimidines by intramolecular cycloaddition of azahexatrienes  
 Yoneda, Fumio; Nagamatsu, Tomohisa; Nagamura, Tetsuya;  
 Senga, Keitaro  
 AUTHOR(S):  
 CORPORATE SOURCE: Fac. Pharm. Sci., Kumamoto Univ., Kumamoto, Japan  
 SOURCE: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1977), (7), 765-7  
 CODEN: JCPRB4; ISSN: 0300-922X  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 87:68272  
 IT 54014-88-9P 54014-89-0P 54014-90-3P  
 54014-91-4P 54014-92-5P 54014-93-6P  
 54058-37-6P 54058-38-7P 63603-87-2P  
 63603-91-8P 63603-92-9P 63603-93-0P  
 63603-94-1P 63603-95-2P 63603-96-3P  
 63603-97-4P 63603-98-5P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 54014-88-9 CAPLUS  
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5,7-dimethyl-3-phenyl-2-(phenylmethyl)- (CA INDEX NAME)



RN 54014-89-0 CAPLUS  
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(4-chlorophenyl)-2-[ (4-chlorophenyl)methyl]-5,7-dimethyl- (CA INDEX NAME)




RN 54014-90-3 CAPLUS  
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(3,4-dichlorophenyl)-2-[ (3,4-dichlorophenyl)methyl]-5,7-dimethyl- (CA INDEX NAME)




RN 54014-91-4 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(4-methoxyphenyl)-2-[(4-methoxyphenyl)methyl]-5,7-dimethyl- (CA INDEX NAME)




RN 54014-92-5 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(4-chlorophenyl)-2-[(4-methoxyphenyl)methyl]-5,7-dimethyl- (CA INDEX NAME)




RN 54014-93-6 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(4-(dimethylamino)phenyl)methyl]-5,7-dimethyl-3-phenyl- (CA INDEX NAME)




RN 54058-37-6 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-3-phenyl-2-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 54058-38-7 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-[4-(dimethylamino)phenyl]-2-[(4-(dimethylamino)phenyl)methyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 63603-87-2 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5,7-dimethyl-3-phenyl-2-(3-phenyl-2-propenyl)- (9CI) (CA INDEX NAME)




RN 63603-91-8 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5,7-dimethyl-3-phenyl-2-(3-phenyl-2-propenyl)- (9CI) (CA INDEX NAME)




RN 63603-92-9 CAPLUS  
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(4-methoxyphenyl)-2-[(4-methoxyphenyl)methyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 63603-93-0 CAPLUS  
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(4-chlorophenyl)-2-[(4-methoxyphenyl)methyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 63603-94-1 CAPLUS  
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5,7-dimethyl-3-phenyl-2-(1-phenylethyl)- (CA INDEX NAME)




RN 63603-95-2 CAPLUS  
 CN 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 6-amino-2,5-dihydro-3-phenyl-2-

(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 63603-96-3 CAPLUS

CN 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 6-amino-3-(4-chlorophenyl)-2-[(4-chlorophenyl)methyl]-2,5-dihydro- (9CI) (CA INDEX NAME)




RN 63603-97-4 CAPLUS

CN 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 6-amino-3-(3,4-dichlorophenyl)-2-[(3,4-dichlorophenyl)methyl]-2,5-dihydro- (9CI) (CA INDEX NAME)




RN 63603-98-5 CAPLUS

CN 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 6-amino-2,5-dihydro-3-(4-methoxyphenyl)-2-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




GI




AB Cyclocondensation reaction of aldehyde 1,3-dimethyluracil-6-yl hydrazones with aromatic aldehydes in DMF gave 2,3-disubstituted 5,7-dimethylpyrazolo[3,4-d]pyrimidinediones. E.g., I ( $R = Me$ ) with PhCHO gave 80% II ( $R = Me$ ). 6-Benzylidenehydrazino-3-methyluracils with aromatic aldehydes in EtOH and DMF gave diazahexatrienes and 3-aryl-2-benzyl-5-methylpyrazolo[3,4-d]pyrimidinediones, resp. E.g., I ( $R = H$ ) with PhCHO gave 88% 5-benzylidene-6-benzylidenehydrazino-3-methyluracil (III) and 68% II ( $R = H$ ). III cyclized to II ( $R = H$ ) in refluxing DMF. 2-Amino-6-benzylidenehydrazino-4-hydroxypyrimidines with aromatic aldehydes in DMF gave 6-amino-3-aryl-2-benzyl-4-hydroxypyrazolo[3,4-d]pyrimidines. E.g., IV gave V.


L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1975:564110 CAPLUS  
 DOCUMENT NUMBER: 83:164110  
 ORIGINAL REFERENCE NO.: 83:25751a, 25754a  
 TITLE: Thermolysis and photolysis of 6-(benzylidenehydrazino)uracils. New syntheses of pyrazolo[3,4-d]pyrimidines. Method to convert aldehydes to nitriles  
 AUTHOR(S): Yoneda, Fumio; Nagamatsu, Tomohisa  
 CORPORATE SOURCE: Fac. Pharm. Sci., Kumamoto Univ., Kumamoto, Japan  
 SOURCE: Bulletin of the Chemical Society of Japan (1975), 48(5), 1484-9  
 CODEN: BCSJA8; ISSN: 0009-2673  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 83:164110  
 IT 54014-88-9P 54014-89-0P 54014-90-3P  
 54014-91-4P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 54014-88-9 CAPLUS  
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5,7-dimethyl-3-phenyl-2-(phenylmethyl)- (CA INDEX NAME)



RN 54014-89-0 CAPLUS  
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(4-chlorophenyl)-2-[ (4-chlorophenyl)methyl]-5,7-dimethyl- (CA INDEX NAME)




RN 54014-90-3 CAPLUS  
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(3,4-dichlorophenyl)-2-[ (3,4-dichlorophenyl)methyl]-5,7-dimethyl- (CA INDEX NAME)



RN 54014-91-4 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(4-methoxyphenyl)-2-[(4-methoxyphenyl)methyl]-5,7-dimethyl- (CA INDEX NAME)



GI For diagram(s), see printed CA Issue.

AB The thermolysis of 6-(benzylidenehydrazino)uracil derivs. generally involves their oxidative cyclization to give the corresponding pyrazolo[3,4-d]pyrimidine derivs. I [R, R1 = Me, H; R2 = Ph, p-ClC6H4, p-MeOC6H4, p-(Me2N)C6H4, 3,4-C12C6H3]. However, the thermolysis of fully methylated 6-(benzylidenehydrazino)uracil gave no pyrazolo[3,4-d]pyrimidines, but mixts. of the respective nitriles and 1,3-dimethyl-6-methylaminouracil. The photolysis of the fully methylated 6-(benzylidenehydrazino)uracils give the pyrazolo[3,4-d]pyrimidines.

L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1974:505449 CAPLUS

DOCUMENT NUMBER: 81:105449

ORIGINAL REFERENCE NO.: 81:16683a,16686a

TITLE: Novel synthetic route to heterocycles via intramolecular cycloaddition of azalogs of hexatriene. New syntheses of purines and pyrazolo[3,4-d]pyrimidines

AUTHOR(S): Yoneda, Fumio; Higuchi, Masatsugu; Nagamatsu, Tomohisa

CORPORATE SOURCE: Fac. Pharm. Sci., Kumamoto Univ., Kumamoto, Japan

SOURCE: Journal of the American Chemical Society (1974), 96(17), 5607-8

CODEN: JACSAT; ISSN: 0002-7863

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 54014-88-9P 54014-89-0P 54014-90-3P


54014-91-4P 54014-92-5P 54014-93-6P

54058-37-6P 54058-38-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)


RN 54014-88-9 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5,7-dimethyl-3-phenyl-2-(phenylmethyl)- (CA INDEX NAME)




RN 54014-89-0 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(4-chlorophenyl)-2-[ (4-chlorophenyl)methyl]-5,7-dimethyl- (CA INDEX NAME)




RN 54014-90-3 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(3,4-dichlorophenyl)-2-[ (3,4-dichlorophenyl)methyl]-5,7-dimethyl- (CA INDEX NAME)




RN 54014-91-4 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(4-methoxyphenyl)-2-[(4-methoxyphenyl)methyl]-5,7-dimethyl- (CA INDEX NAME)




RN 54014-92-5 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(4-chlorophenyl)-2-[(4-methoxyphenyl)methyl]-5,7-dimethyl- (CA INDEX NAME)




RN 54014-93-6 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(4-(dimethylamino)phenyl)methyl]-5,7-dimethyl-3-phenyl- (CA INDEX NAME)




RN 54058-37-6 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-3-phenyl-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 54058-38-7 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(4-chlorophenyl)-2-[(4-chlorophenyl)methyl]-5-methyl- (9CI) (CA INDEX NAME)



GI For diagram(s), see printed CA Issue.

AB The thermolysis of 5-(arylazo)-1,3-dimethyl-6-[(dimethylamino)methylene]amino]-uracils gave 8-(dimethylamino)theophylline and 5-aryl-1,3-dimethyl-7-(dimethylamino)-5,6(or 5,8)-dihydro-6-azalumazines. The reaction of 6-amino-1,3-dimethyl-5-(phenylazo)uracil with aromatic aldehydes gave the corresponding 8-aryltheophyllines and 5-aryl-1,3-dimethyl-7-phenyl-5,6(or 5,8)-dihydro-6-azalumazines. This purine synthesis is applicable to other 6-amino-5-(phenylazo)pyrimidines such as 6-amino-1-methyl-5-(phenylazo)uracil and 6-amino-4-hydroxy-2-phenyl-5-(phenylazo)pyrimidine to give the resp. purine derivs. Heating 6-(benzylidene-hydrazino)uracil derivs. with aromatic aldehydes in DMF gave the corresponding 3-aryl-2-benzylpyrazolo[3,4-d] pyrimidine-4,6(5H,-7H)-diones I in excellent yields.

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	55.46	234.49
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-8.00	-8.00

STN INTERNATIONAL LOGOFF AT 19:55:37 ON 09 APR 2008